Document And Entity Information
Document And Entity Information - shares | 9 Months Ended | |
Sep. 30, 2021 | Nov. 10, 2021 | |
Document Information [Line Items] | ||
Entity Central Index Key | 0001389545 | |
Entity Registrant Name | NOVABAY PHARMACEUTICALS, INC. | |
Amendment Flag | false | |
Current Fiscal Year End Date | --12-31 | |
Document Fiscal Period Focus | Q3 | |
Document Fiscal Year Focus | 2021 | |
Document Type | 10-Q | |
Document Quarterly Report | true | |
Document Period End Date | Sep. 30, 2021 | |
Document Transition Report | false | |
Entity File Number | 001-33678 | |
Entity Incorporation, State or Country Code | DE | |
Entity Tax Identification Number | 68-0454536 | |
Entity Address, Address Line One | 2000 Powell Street, Suite 1150 | |
Entity Address, City or Town | Emeryville | |
Entity Address, State or Province | CA | |
Entity Address, Postal Zip Code | 94608 | |
City Area Code | 510 | |
Local Phone Number | 899-8800 | |
Title of 12(b) Security | Common Stock, par value $0.01 per share | |
Trading Symbol | NBY | |
Security Exchange Name | NYSE | |
Entity Current Reporting Status | Yes | |
Entity Interactive Data Current | Yes | |
Entity Emerging Growth Company | false | |
Entity Filer Category | Non-accelerated Filer | |
Entity Small Business | true | |
Entity Shell Company | false | |
Entity Common Stock, Shares Outstanding | 44,943,364 |
Condensed Consolidated Balance
Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($) $ in Thousands | Sep. 30, 2021 | Dec. 31, 2020 |
ASSETS | ||
Cash and cash equivalents | $ 9,028 | $ 11,952 |
Accounts receivable, net of allowance for doubtful accounts ($0 at September 30, 2021 and December 31, 2020) | 843 | 1,106 |
Inventory, net of allowance for excess and obsolete inventory ($149 and $236 at September 30, 2021 and December 31, 2020, respectively) | 969 | 608 |
Prepaid expenses and other current assets | 657 | 576 |
Total current assets | 11,497 | 14,242 |
Operating lease right-of-use assets | 170 | 436 |
Property and equipment, net | 96 | 84 |
Other assets | 476 | 476 |
TOTAL ASSETS | 12,239 | 15,238 |
LIABILITIES AND STOCKHOLDERS' EQUITY | ||
Accounts payable | 1,354 | 302 |
Accrued liabilities | 1,325 | 2,115 |
Operating lease liability | 195 | 416 |
Total current liabilities | 2,874 | 2,833 |
Operating lease liabilities-non-current | 1 | 87 |
Total liabilities | 2,875 | 2,920 |
Commitments & contingencies (Note 8) | ||
Stockholders' equity: | ||
Preferred stock: 5,000 shares authorized; none issued and outstanding at September 30, 2021 and December 31, 2020 | 0 | 0 |
Common stock, $0.01 par value; 100,000 and 75,000 shares authorized at September 30, 2021 and December 31, 2020, respectively; 44,943 and 41,782 shares issued and outstanding at September 30, 2021 and December 31, 2020, respectively | 450 | 418 |
Additional paid-in capital | 150,643 | 147,963 |
Accumulated deficit | (141,729) | (136,063) |
Total stockholders' equity | 9,364 | 12,318 |
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY | $ 12,239 | $ 15,238 |
Condensed Consolidated Balanc_2
Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - USD ($) $ in Thousands | Sep. 30, 2021 | Dec. 31, 2020 |
Accounts receivable, allowance for doubtful accounts | $ 0 | $ 0 |
Inventory, allowance for excess and obsolete inventory and lower of cost or estimated net realizable value adjustments | $ 149 | $ 236 |
Preferred stock, shares authorized (in shares) | 5,000,000 | 5,000,000 |
Preferred stock, shares outstanding (in shares) | 0 | 0 |
Preferred stock, shares issued (in shares) | 0 | 0 |
Common stock, par value (in dollars per share) | $ 0.01 | $ 0.01 |
Common stock, shares authorized (in shares) | 100,000,000 | 75,000,000 |
Common stock, shares issued (in shares) | 44,943,000 | 41,782,000 |
Common stock, shares outstanding (in shares) | 44,943,000 | 41,782,000 |
Condensed Consolidated Statemen
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) shares in Thousands, $ in Thousands | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2021 | Sep. 30, 2020 | Sep. 30, 2021 | Sep. 30, 2020 | |
Sales: | ||||
Total sales, net | $ 1,840 | $ 2,170 | $ 5,780 | $ 8,046 |
Product cost of goods sold | 493 | 536 | 1,562 | 3,157 |
Gross profit | 1,347 | 1,634 | 4,218 | 4,889 |
Operating expenses: | ||||
Research and development | 10 | 125 | 36 | 249 |
Sales and marketing | 1,855 | 1,692 | 5,323 | 4,675 |
General and administrative | 1,771 | 1,879 | 4,527 | 4,633 |
Total operating expenses | 3,636 | 3,696 | 9,886 | 9,557 |
Operating loss | (2,289) | (2,062) | (5,668) | (4,668) |
Non-cash loss on changes in fair value of warrant liability | 0 | (1,589) | 0 | (5,224) |
Non-cash gain on changes in fair value of embedded derivative liability | 0 | 1 | 0 | 3 |
Other income, net | 0 | 429 | 2 | 605 |
Loss before provision for income taxes | (2,289) | (3,221) | (5,666) | (9,284) |
Provision for income taxes | 0 | 0 | 0 | (1) |
Net loss and comprehensive loss | $ (2,289) | $ (3,221) | $ (5,666) | $ (9,285) |
Net loss per share (basic and diluted) (in dollars per share) | $ (0.05) | $ (0.08) | $ (0.13) | $ (0.28) |
Weighted-average shares of common stock used in computing net loss per share (basic and diluted) (in shares) | 44,921 | 40,037 | 43,100 | 32,614 |
Product [Member] | ||||
Sales: | ||||
Total sales, net | $ 1,834 | $ 2,167 | $ 5,761 | $ 8,038 |
Product and Service, Other [Member] | ||||
Sales: | ||||
Total sales, net | $ 6 | $ 3 | $ 19 | $ 8 |
Condensed Consolidated Statem_2
Condensed Consolidated Statements of Stockholders' Equity (Deficit) (Unaudited) - USD ($) shares in Thousands, $ in Thousands | Employee [Member]Common Stock [Member] | Employee [Member]Additional Paid-in Capital [Member] | Employee [Member]AOCI Attributable to Parent [Member] | Employee [Member] | Common Stock [Member] | Additional Paid-in Capital [Member] | AOCI Attributable to Parent [Member] | Total |
Balance (in shares) at Dec. 31, 2019 | 27,938 | |||||||
Balance at Dec. 31, 2019 | $ 279 | $ 125,718 | $ (125,024) | $ 973 | ||||
Net loss | 0 | 0 | (1,582) | (1,582) | ||||
Stock-based compensation expense related to employee and director stock options | 0 | 45 | 0 | 45 | ||||
Stock-based compensation expense related to non-employee stock options | $ 0 | 12 | 0 | 12 | ||||
Vesting of employee restricted stock awards (in shares) | 2 | |||||||
Vesting of employee restricted stock awards | $ 0 | $ 2 | $ 0 | $ 2 | ||||
Issuance of common stock in connection with exercise of warrants (in shares) | 299 | |||||||
Issuance of common stock in connection with exercise of warrants | $ 3 | 198 | 0 | 201 | ||||
Balance (in shares) at Mar. 31, 2020 | 28,239 | |||||||
Balance at Mar. 31, 2020 | $ 282 | 125,975 | (126,606) | (349) | ||||
Balance (in shares) at Dec. 31, 2019 | 27,938 | |||||||
Balance at Dec. 31, 2019 | $ 279 | 125,718 | (125,024) | 973 | ||||
Net loss | $ (9,285) | |||||||
Issuance of stock for option exercises (in shares) | 20 | |||||||
Balance (in shares) at Sep. 30, 2020 | 41,760 | |||||||
Balance at Sep. 30, 2020 | $ 417 | 147,774 | (134,309) | $ 13,882 | ||||
Balance (in shares) at Mar. 31, 2020 | 28,239 | |||||||
Balance at Mar. 31, 2020 | $ 282 | 125,975 | (126,606) | (349) | ||||
Net loss | 0 | 0 | (4,482) | (4,482) | ||||
Stock-based compensation expense related to employee and director stock options | 0 | 92 | 0 | 92 | ||||
Stock-based compensation expense related to non-employee stock options | $ 0 | (2) | 0 | (2) | ||||
Issuance of common stock, net of offering costs (in shares) | 5,838 | |||||||
Issuance of common stock, net of offering costs | $ 58 | 5,162 | 0 | 5,220 | ||||
Issuance of common stock in connection with exercise of warrants (in shares) | 571 | |||||||
Issuance of common stock in connection with exercise of warrants | $ 6 | 462 | 0 | 468 | ||||
Stock option modification | $ 0 | 36 | 0 | 36 | ||||
Balance (in shares) at Jun. 30, 2020 | 34,648 | |||||||
Balance at Jun. 30, 2020 | $ 346 | 131,725 | (131,088) | 983 | ||||
Net loss | 0 | 0 | (3,221) | (3,221) | ||||
Stock-based compensation expense related to employee and director stock options | 0 | 142 | 0 | 142 | ||||
Stock-based compensation expense related to non-employee stock options | $ 0 | 17 | 0 | 17 | ||||
Vesting of employee restricted stock awards (in shares) | 193 | |||||||
Vesting of employee restricted stock awards | $ 2 | 218 | 0 | 220 | ||||
Issuance of common stock in connection with exercise of warrants (in shares) | 6,899 | |||||||
Issuance of common stock in connection with exercise of warrants | $ 69 | 6,356 | 0 | 6,425 | ||||
Stock option modification | 0 | 17 | 0 | 17 | ||||
Reclassification of warrant liability to equity – see Note 11 | $ 0 | 9,293 | 0 | $ 9,293 | ||||
Issuance of stock for option exercises (in shares) | 20 | 20 | ||||||
Issuance of stock for option exercises | $ 0 | 6 | 0 | $ 6 | ||||
Balance (in shares) at Sep. 30, 2020 | 41,760 | |||||||
Balance at Sep. 30, 2020 | $ 417 | 147,774 | (134,309) | 13,882 | ||||
Balance (in shares) at Dec. 31, 2020 | 41,782 | |||||||
Balance at Dec. 31, 2020 | $ 418 | 147,963 | (136,063) | 12,318 | ||||
Net loss | 0 | 0 | (1,518) | (1,518) | ||||
Stock-based compensation expense related to employee and director stock options | 0 | 130 | 0 | 130 | ||||
Stock-based compensation expense related to non-employee stock options | $ 0 | 53 | 0 | 53 | ||||
Balance (in shares) at Mar. 31, 2021 | 41,782 | |||||||
Balance at Mar. 31, 2021 | $ 418 | 148,146 | (137,581) | 10,983 | ||||
Balance (in shares) at Dec. 31, 2020 | 41,782 | |||||||
Balance at Dec. 31, 2020 | $ 418 | 147,963 | (136,063) | 12,318 | ||||
Net loss | $ (5,666) | |||||||
Issuance of stock for option exercises (in shares) | 0 | |||||||
Balance (in shares) at Sep. 30, 2021 | 44,943 | |||||||
Balance at Sep. 30, 2021 | $ 450 | 150,643 | (141,729) | $ 9,364 | ||||
Balance (in shares) at Mar. 31, 2021 | 41,782 | |||||||
Balance at Mar. 31, 2021 | $ 418 | 148,146 | (137,581) | 10,983 | ||||
Net loss | 0 | 0 | (1,859) | (1,859) | ||||
Stock-based compensation expense related to employee and director stock options | 0 | 242 | 0 | 242 | ||||
Stock-based compensation expense related to non-employee stock options | 0 | 54 | 0 | 54 | ||||
Issuance of warrants | $ 0 | 13 | 0 | 13 | ||||
Issuance of common stock, net of offering costs (in shares) | 2,673 | |||||||
Issuance of common stock, net of offering costs | $ 27 | 1,749 | 0 | 1,776 | ||||
Vesting of employee restricted stock awards (in shares) | 160 | |||||||
Vesting of employee restricted stock awards | $ 2 | (2) | 0 | 0 | ||||
Balance (in shares) at Jun. 30, 2021 | 44,615 | |||||||
Balance at Jun. 30, 2021 | $ 447 | 150,202 | (139,440) | 11,209 | ||||
Net loss | 0 | 0 | (2,289) | (2,289) | ||||
Stock-based compensation expense related to employee and director stock options | 0 | 151 | 0 | 151 | ||||
Stock-based compensation expense related to non-employee stock options | $ 0 | 73 | 0 | 73 | ||||
Vesting of employee restricted stock awards (in shares) | 328 | |||||||
Vesting of employee restricted stock awards | $ 3 | 217 | 0 | $ 220 | ||||
Issuance of stock for option exercises (in shares) | 0 | |||||||
Balance (in shares) at Sep. 30, 2021 | 44,943 | |||||||
Balance at Sep. 30, 2021 | $ 450 | $ 150,643 | $ (141,729) | $ 9,364 |
Condensed Consolidated Statem_3
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands | 9 Months Ended | |
Sep. 30, 2021 | Sep. 30, 2020 | |
Operating activities: | ||
Net loss | $ (5,666) | $ (9,285) |
Adjustments to reconcile net loss to net cash used in operating activities: | ||
Depreciation and amortization | 32 | 40 |
Gain on early termination of lease | 0 | (54) |
(Loss) on disposal of property and equipment | 0 | (1) |
Stock option modification expense | 0 | 53 |
Vesting of employee restricted stock awards | 2 | 2 |
Issuance of warrants | 0 | 0 |
Issuance of RSU’s to non-employees for services | 13 | 220 |
Non-cash loss on changes in fair value of warrant liability | 0 | 5,224 |
Non-cash (gain) on changes in fair value of embedded derivative liability | 0 | (3) |
Interest expense related to amortization of debt issuance and debt discount | 0 | 141 |
Interest expense related to amortization of debt issuance related to related party notes payable | 0 | 2 |
Changes in operating assets and liabilities: | ||
Accounts receivable | 263 | (226) |
Inventory | (361) | (293) |
Prepaid expenses and other current assets | (81) | 191 |
Operating lease right-of-use assets | 266 | 734 |
Other assets | 0 | 1 |
Accounts payable and accrued liabilities | 262 | 355 |
Operating lease liabilities | (307) | (784) |
Other current liabilities | 0 | 28 |
Related party notes payable | 0 | 73 |
Net cash used in operating activities | (4,874) | (3,276) |
Investing activities: | ||
Purchases of property and equipment | (44) | (5) |
Net cash used in investing activities | (44) | (5) |
Financing activities: | ||
Proceeds from common stock issuances, net | 1,994 | 5,220 |
Proceeds from exercise of options | 0 | 6 |
Proceeds from exercise of warrants | 0 | 7,094 |
Payment on the Convertible Note (see Note 10) | 0 | (1,563) |
Payment on the Promissory Note (see Note 9) | 0 | (1,000) |
Net cash provided by financing activities | 1,994 | 9,757 |
Net (decrease) increase in cash, cash equivalents, and restricted cash | (2,924) | 6,476 |
Cash, cash equivalents and restricted cash, beginning of year | 12,427 | 7,412 |
Cash, cash equivalents and restricted cash, end of period | 9,503 | 13,888 |
Supplemental disclosure of cash flow information: | ||
Interest paid | 0 | 61 |
Supplemental disclosure of non-cash information: | ||
Warrant liability transferred to equity | 0 | 9,293 |
Non-cash payment of related party loan accrued interest offset by related party accounts receivable | 0 | 173 |
Employees and Directors [Member] | Share-based Payment Arrangement, Option [Member] | ||
Adjustments to reconcile net loss to net cash used in operating activities: | ||
Stock-based compensation expense for options and stock issued | 523 | 279 |
Nonemployees [Member] | Share-based Payment Arrangement, Option [Member] | ||
Adjustments to reconcile net loss to net cash used in operating activities: | ||
Stock-based compensation expense for options and stock issued | $ 180 | $ 27 |
Note 1 - Organization
Note 1 - Organization | 9 Months Ended |
Sep. 30, 2021 | |
Notes to Financial Statements | |
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] | 1. NovaBay Pharmaceuticals, Inc. (the “Company”) is a medical device company predominantly focused on eye care. A majority of our revenue comes from Avenova®, an FDA cleared product sold in the United States that has proven in laboratory testing to have broad antimicrobial properties as it removes foreign material including microorganisms and debris from skin around the eye, including the eyelid. Avenova is formulated with our proprietary, stable and pure form of hypochlorous acid. Avenova is available directly to consumers through our online sales channel and is also often prescribed and dispensed by eyecare professionals for blepharitis and dry-eye disease. We continue to promote Avenova through all four 1 2 50 3 4 Avenova was launched as a prescription only product in 2016. second 2019. not The launch of over-the-counter Avenova online proved to be especially fortuitous during the COVID- 19 Over-the-counter Avenova is now our leading product by unit sales and net revenue despite having a lower average net selling price than Avenova sold through pharmacy channels. This sales performance reflects our ongoing focus and spend on digital marketing, social media and public relations initiatives to promote Avenova directly to the end consumer. Avenova is available on Amazon.com, Walmart.com, and Avenova.com. Beginning in February 2021, one Although we expect the online sales channel to continue to be our fastest-growing channel, support for Avenova from the medical community is important to maintaining its reputation as a preferred product. The “doctor recommended” halo effect around our brand remains strong due in part to our continued promotion of prescription Avenova. Earlier this year, we launched a rebranded CelleRx® into the beauty industry as CelleRx® Clinical Reset™. Clinical Reset is formulated with NovaBay’s patented, pure, prescription-grade hypochlorous acid, a naturally occurring oxidant that is also produced by white blood cells within the human body. It keeps the skin’s natural barrier intact, which when out of balance can allow acne, rosacea and infection to set in. Clinical Reset is complementary to a daily beauty regime for use on clean skin or over makeup. Beyond Avenova and CelleRx, we have developed additional products containing our proprietary, stable and pure form of hypochlorous acid, including NeutroPhase® and PhaseOne® for the wound care market. NeutroPhase is only sold in China through our exclusive distributor, Pioneer Pharma Co. Ltd. PhaseOne is only sold in the United States through our exclusive distributor, PhaseOne Health, LLC. Last year, we responded to the national need for protective personal equipment (“PPE”) by tapping into our international supply network and launching the sale of third KN95 “KN95 KN95 second 2020, not not During the second two not Liquidity Based on our funds available on September 30, 2021, November 2, 2021, November 12, 2022, 18, may may 19 |
Note 2 - Summary of Significant
Note 2 - Summary of Significant Accounting Policies | 9 Months Ended |
Sep. 30, 2021 | |
Notes to Financial Statements | |
Significant Accounting Policies [Text Block] | NOTE 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) and are expressed in U.S. dollars. Use of Estimates The preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. These estimates include contract liabilities related to product sales, useful lives for property and equipment and related depreciation calculations, assumptions for valuing options and warrants, income taxes and other contingencies. Actual results could differ from those estimates. Unaudited Interim Financial Information The accompanying unaudited interim condensed consolidated financial statements and related disclosures have been prepared on the same basis as the annual consolidated financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary for a fair statement of the results of operations for the periods presented. The year-end condensed consolidated balance sheet data was derived from audited financial statements but does not not The financial statements and notes included herein should be read in conjunction with the annual financial statements and notes for the year ended December 31, 2020, 10 December 31, 2020, March 25, 2021. Cash, Cash Equivalents, and Restricted Cash The Company considers all highly-liquid instruments with a stated maturity of three September 30, 2021 December 31, 2020, The following table provides a reconciliation of the cash, cash equivalents, and restricted cash reported in the condensed consolidated balance sheets that sum to the total of the same reported in the condensed consolidated statements of cash flows (in thousands): September 30, December 31, 2021 2020 Cash and cash equivalents $ 9,028 $ 11,952 Restricted cash included in other assets 475 475 Total cash, cash equivalents, and restricted cash in the condensed consolidated statements of cash flows $ 9,503 $ 12,427 The restricted cash amount included in other assets on the condensed consolidated balance sheets represents amounts held as certificates of deposit for Company credit cards and lease arrangements as contractually required by our financial institution and landlord. Concentrations of Credit Risk and Major Partners Financial instruments that potentially subject us to significant concentrations of credit risk consist primarily of cash, cash equivalents and restricted cash. The Company maintains deposits of cash, cash equivalents and restricted cash with a highly-rated, major financial institution in the United States. Deposits in this bank may not During the three nine September 30, 2021 2020, nine 2020, second KN95 During the three nine September 30, 2021 2020, Three Months Ended September 30, Nine months Ended September 30, 2021 2020 2021 2020 Avenova $ 1,763 $ 1,835 $ 5,221 $ 4,509 KN95 Masks — 69 — 3,081 Other products 71 263 540 448 Total product revenue, net 1,834 2,167 5,761 8,038 Other revenue, net 6 3 19 8 Total sales, net $ 1,840 $ 2,170 $ 5,780 $ 8,046 During the three September 30, 2021 2020, nine September 30, 2021 2020, No 10% three nine September 30, 2021 2020. As of September 30, 2021 December 31, 2020, 10% September 30, December 31, Major distribution partner 2021 2020 Avenova Direct via Amazon 26 % 11 % Distributor A 18 % 18 % Distributor B 16 % 14 % Chongqing Pioneer Pharma Holdings Limited 15 % 16 % Distributor C * % 14 % *Not greater than 10% The Company relies on two not third may may not may 19 Fair Value of Financial Assets and Liabilities The Company’s financial instruments include cash and cash equivalents, restricted cash, accounts receivable, accounts payable, and accrued liabilities. The Company’s cash and cash equivalents, accounts receivable, accounts payable, and accrued liabilities are carried at cost, which management believes approximates fair value due to the short-term nature of these instruments. The Company follows Accounting Standards Codification (“ASC”) 820, Fair Value Measurements and Disclosures three may Level 1 Level 2 Level 3 Categorization within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement. Allowance for Doubtful Accounts The Company charges bad debt expense and records an allowance for doubtful accounts when management believes it to be unlikely that specific invoices will be collected. Management identifies amounts due that are in dispute and it believes are unlikely to be collected. At September 30, 2021 December 31, 2020, Inventory Inventory is comprised of ( 1 2 3 first first September 30, 2021 December 31, 2020, Property and Equipment Property and equipment are stated at cost, less accumulated depreciation and amortization. Depreciation is calculated using the straight-line method over the estimated useful lives of the related assets of five seven three seven The costs of normal maintenance, repairs, and minor replacements are expensed as incurred. Leases At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present. Operating lease liabilities and their corresponding right-of-use assets are recorded based on the present value of lease payments over the expected lease term. The interest rate implicit in lease contracts is typically not may The Company has elected to combine lease and non-lease components as a single component for all leases in which it is a lessee or a lessor. The lease expense is recognized over the expected term on a straight-line basis. Operating leases are recognized on the balance sheet as right-of-use assets, operating lease liabilities current and operating lease liabilities non-current. As a result, as of the effective date, the Company no Comprehensive Income (Loss) ASC 220, Comprehensive Income, Revenue Recognition Revenue generated through the Company’s webstores, Avenova.com and CelleRx.com, for Avenova and CelleRx (as well as the KN95 third Revenue generated through Amazon.com and Walmart.com third The Company also generates Avenova product revenue through product sales to its major distribution partners. Product supply of Avenova is the only performance obligation contained in these arrangements, and the Company recognizes product revenue upon transfer of control to its major distribution partners at the amount of consideration that the Company expects to be entitled to, generally upon receipt by the distributor on a “sell-in” basis. Upon recognition of product sales, contract liabilities are recorded for invoiced amounts that are subject to significant reversal, including product revenue allowances for cash consideration paid to customers for services, discounts, rebate programs, and product returns. The Company derives its rate of return from historical data and updates its return rate assumption quarterly. Payment for product supply is typically due 30 Revenue generated through the Company’s partner pharmacies is recognized when control of the product transfers to the end customer. Revenue for product sales to CVS is recognized upon transfer of control to CVS, which generally occurs upon delivery of the related products to a third Cost of Goods Sold Cost of goods sold includes third Research and Development Costs The Company charges research and development costs to expense as incurred. These costs include all costs associated with research, development and regulatory activities, including submissions to the Food and Drug Administration (“FDA”). Patent Costs Patent costs, including legal expenses, are expensed in the period in which they are incurred. Patent expenses are included in general and administrative expenses in the condensed consolidated statements of operations and comprehensive loss. Advertising Costs Advertising costs are expensed in the period in which the costs are incurred. Advertising expenses were $0.8 million and $0.5 million for the three September 30, 2021 2020, nine September 30, 2021 2020, Stock-Based Compensation The Company’s stock-based compensation includes grants of stock options and restricted stock units (“RSUs”) to employees, consultants and non-employee directors. The expense associated with these grants is recognized in the Company’s condensed consolidated statements of stockholders’ equity (deficit) based on their fair values as they are earned under the applicable vesting terms. For stock options granted, the fair value of the stock options is estimated using a Black-Scholes option pricing model. See Note 13, Income Taxes The Company accounts for income taxes under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is recognized if it is more likely than not not Common Stock Warrant Liability The Company accounts for common stock purchase warrants issued in connection with its equity offerings in accordance with the provisions of ASC 480, Distinguishing Liabilities from Equity 815, Derivatives and Hedging The Company accounts for common stock purchase warrants issued in connection with share-based compensation arrangements in accordance with the provisions of ASC 718, Stock Compensation, 480, Distinguishing Liabilities from Equity The Company classifies as equity any contracts that (i) require physical settlement or net-share settlement or (ii) give the Company a choice of net-cash settlement or settlement in its own shares (physical settlement or net-share settlement). The Company classifies as assets or liabilities any contracts that (i) require net-cash settlement (including a requirement to net-cash settle the contract if an event occurs and if that event is outside the control of the Company) or (ii) give the counterparty a choice of net-cash settlement or settlement in shares (physical settlement or net-share settlement). Additionally, for common stock purchase warrants accounted for in accordance with ASC 718, Stock Compensation, For warrants that are classified as liabilities, the Company records the fair value of the warrants at each balance sheet date and records changes in the estimated fair value as a non-cash gain or loss in the consolidated statements of operations and comprehensive loss. The fair values of these warrants are determined using the Black-Scholes option pricing model, the Binomial Lattice (“Lattice”) valuation model, or the Monte Carlo simulation model where deemed appropriate. These values are subject to a significant degree of management’s judgment. Net Loss Per Share The Company computes net loss per share by presenting both basic and diluted earnings (loss) per share (“EPS”). Basic EPS is computed by dividing net loss available to common stockholders by the weighted average number of common shares outstanding during the period. Diluted EPS gives effect to all dilutive potential common shares outstanding during the period, including stock options and warrants, using the treasury stock method. In computing diluted EPS, the average stock price for the period is used to determine the number of shares assumed to be purchased from the exercise of stock options or warrants. Potentially dilutive common share equivalents are excluded from the diluted EPS computation in net loss periods because their effect would be anti-dilutive. We have incurred a net loss for all periods presented in the unaudited condensed consolidated statements of operations and comprehensive loss. The following common stock equivalents were not As of September 30, 2021 2020 Stock options 3,947 3,328 Stock warrants 7,082 7,067 11,029 10,395 Recent Accounting Pronouncements For information regarding recent accounting pronouncements that could affect our business, results of operations, financial condition, and liquidity, see Note 2, 10 December 31, 2020, March 25, 2021. no |
Note 3 - Fair Value Measurement
Note 3 - Fair Value Measurements | 9 Months Ended |
Sep. 30, 2021 | |
Notes to Financial Statements | |
Fair Value Disclosures [Text Block] | NOTE 3. The Company’s cash equivalents are classified within Level 1 1 The following table presents the Company’s assets measured at fair value on a recurring basis as of September 30, 2021 ( Fair Value Measurements Using Assets Balance at September 30, 2021 Quoted Prices in Active Markets for Identical Items (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Restricted cash held as a certificate of deposit $ 324 $ 324 $ — $ — Deposit held as a certificate of deposit 151 151 — — Total assets $ 475 $ 475 $ — $ — The following table presents the Company's assets measured at fair value on a recurring basis as of December 31, 2020 ( Fair Value Measurements Using Assets Balance at December 31, 2020 Quoted Prices in Active Markets for Identical Items (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Restricted cash held as a certificate of deposit $ 324 $ 324 $ — $ — Deposit held as a certificate of deposit 151 151 — — Total assets $ 475 $ 475 $ — $ — There were no September 30, 2021 December 31, 2020. |
Note 4 - Prepaid Expenses and O
Note 4 - Prepaid Expenses and Other Current Assets | 9 Months Ended |
Sep. 30, 2021 | |
Notes to Financial Statements | |
Prepaid Expenses and Other Current Assets [Text Block] | NOTE 4. Prepaid expenses and other current assets consisted of the following (in thousands): September 30, December 31, 2021 2020 Prepaid inventory $ 214 $ — Prepaid insurance 150 165 Prepaid financing costs 104 — Prepaid sales rebates (Avenova contract asset) 44 144 Prepaid dues and subscriptions 18 53 Prepaid patents 10 47 Prepaid security deposit for lease — 65 Other 117 102 Total prepaid expenses and other current assets $ 657 $ 576 |
Note 5 - Inventory
Note 5 - Inventory | 9 Months Ended |
Sep. 30, 2021 | |
Notes to Financial Statements | |
Inventory Disclosure [Text Block] | NOTE 5. Inventory consisted of the following (in thousands): September 30, December 31, 2021 2020 Raw materials and supplies $ 271 $ 159 Finished goods 847 685 Less: Reserve for excess and obsolete inventory (149 ) (236 ) Total inventory, net $ 969 $ 608 |
Note 6 - Property and Equipment
Note 6 - Property and Equipment | 9 Months Ended |
Sep. 30, 2021 | |
Notes to Financial Statements | |
Property, Plant and Equipment Disclosure [Text Block] | NOTE 6. Property and equipment consisted of the following (in thousands): September 30, December 31, 2021 2020 Computer equipment and software $ 409 $ 365 Furniture and fixtures 157 157 Leasehold improvements 79 79 Production equipment 65 65 Office equipment 20 20 Total property and equipment, at cost 730 686 Less: accumulated depreciation and amortization (634 ) (602 ) Total property and equipment, net $ 96 $ 84 Depreciation and amortization expense was $13 thousand and $12 thousand for the three September 30, 2021 2020, nine September 30, 2021 2020, |
Note 7 - Accrued Liabilities
Note 7 - Accrued Liabilities | 9 Months Ended |
Sep. 30, 2021 | |
Notes to Financial Statements | |
Accounts Payable and Accrued Liabilities Disclosure [Text Block] | NOTE 7. Accrued liabilities consisted of the following (in thousands): September 30, December 31, 2021 2020 Avenova contract liabilities $ 579 $ 730 Employee payroll and benefits 396 632 Sublease security deposit — 198 Inventory purchases — 181 Consulting services — 98 Other 350 276 Total accrued liabilities $ 1,325 $ 2,115 |
Note 8 - Commitments and Contin
Note 8 - Commitments and Contingencies | 9 Months Ended |
Sep. 30, 2021 | |
Notes to Financial Statements | |
Commitments and Contingencies Disclosure [Text Block] | NOTE 8. Directors and Officers Indemnification As permitted under Delaware law and in accordance with its bylaws, the Company indemnifies its officers and directors for certain events or occurrences while the officer or director is or was serving at the Company’s request in such capacity. The term of the indemnification period is for the officer’s or director’s lifetime. The maximum amount of potential future indemnification is unlimited; however, the Company has a director and officer insurance policy that limits its exposure and may not September 30, 2021. In the normal course of business, the Company provides indemnification of varying scope under its agreements with other companies, typically its clinical research organizations, investigators, clinical sites, suppliers and others. Pursuant to these agreements, it generally indemnifies, holds harmless, and agrees to reimburse the indemnified parties for losses suffered or incurred by the indemnified parties in connection with the use or testing of its products or product candidates or with any U.S. patent or any copyright or other intellectual property infringement claims by any third not September 30, 2021. Legal Matters On July 29, 2019, December 2020. The Company’s insurance carrier determined that the Company was entitled to a $0.3 million reimbursement for litigation costs incurred in conjunction with the McGovern matter. The Company received a $0.3 million reimbursement on April 23, 2021 three March 31, 2021. As of September 30, 2021, no Leases The Company leases office space for its corporate headquarters located in Emeryville, California. The initial lease term is through February 28, 2022. one five The Company also had a lease commitment for laboratory facilities and office space at EmeryStation North in Emeryville, California (“EmeryStation”) under an operating lease. In July 2016, September 8, 2016. August 31, 2020 July 31, 2020. The components of lease expense for the three nine September 30, 2021 2020 Lease Costs Three Months Ended September 30, Nine months Ended September 30, 2021 2020 2021 2020 Operating lease cost $ 99 $ 212 $ 298 $ 726 Sublease income — (105 ) — (421 ) Net lease cost $ 99 $ 107 $ 298 $ 305 Other information Operational cash flow used for operating leases $ 113 $ 236 $ 339 $ 816 The Company has measured its operating lease liabilities at its incremental borrowing rate over the remaining term for each operating lease. The weighted average remaining lease term and the weighted average discount rate are summarized as follows: September 30, 2021 September 30, 2020 Weighted-average remaining lease term (in years) 0.5 1.5 Weighted-average discount rate 12 % 12 % Future lease payments under non-cancelable leases as of September 30, 2021 2021 $ 114 2022 88 Total future minimum lease payments 202 Less imputed interest (6 ) Total $ 196 Reported as: Operating lease liability $ 195 Operating lease liability- non-current 1 Total $ 196 |
Note 9 - Related Party Note Pay
Note 9 - Related Party Note Payable | 9 Months Ended |
Sep. 30, 2021 | |
Notes to Financial Statements | |
Related Party Notes Payable [Text Block] | NOTE 9. PAYABLE On February 27, 2019, September 25, 2019 May 14, 2020 ( 65,178 40ml second May 14, 2020, 12, two 2020. December 31, 2020, In connection with the Promissory Note, the Company one March 1, 2020 ( no The interest expense recognized, including amortization of the issuance costs, was $0 and $75 thousand during the three nine September 30, 2020, three nine September 30, 2021. |
Note 10 - Convertible Note
Note 10 - Convertible Note | 9 Months Ended |
Sep. 30, 2021 | |
Notes to Financial Statements | |
Debt Disclosure [Text Block] | NOTE 10. On March 26, 2019, March 26, 2019. September 26, 2020, third 2020. During the three nine September 30, 2020, three nine September 30, 2020, three nine September 30, 2021. |
Note 11 - Warrant Liability
Note 11 - Warrant Liability | 9 Months Ended |
Sep. 30, 2021 | |
Notes to Financial Statements | |
Other Liabilities Disclosure [Text Block] | NOTE 11. July 2011 The Company issued the July 2011 12, third 2011. July 2011 480, Distinguishing Liabilities from Equity July 2011 On March 6, 2020, July 2011 July 2011 September 30, 2021. October 2015 The Company issued the October 2015 12, third 2015. October 2015 480, Distinguishing Liabilities from Equity October 2015 During the fourth 2020, October 2015 On October 27, 2020, October 2015 October 2015 September 30, 2021. 2019 As further described in Note 12, 2019 2019 2019 third 2019. 2019 2019 2019 480, Distinguishing Liabilities from Equity Upon issuance in the third 2019, 2019 2019 2019 In the third 2020, 12, 2019 2019 2019 2019 Assumptions 2019 Domestic Warrants 2019 Foreign Warrants Expected price volatility 178 % 178 % Expected term (in years) 4.57 4.57 Risk-free interest rate 0.25 % 0.27 % Dividend yield 0.00 % 0.00 % Weighted-average fair value of warrant $ 1.18 $ 1.54 There were no 2019 2019 September 30, 2021. In the third 2020, 12, 2019 2019 no 2019 Expected price volatility 186 % Expected term (in years) 4.05 Risk-free interest rate 0.22 % Dividend yield 0.00 % Weighted-average fair value of warrants $ 1.17 The 2019 no 2019 September 30, 2021. |
Note 12 - Stockholders' Equity
Note 12 - Stockholders' Equity | 9 Months Ended |
Sep. 30, 2021 | |
Notes to Financial Statements | |
Stockholders' Equity Note Disclosure [Text Block] | NOTE 12. EQUITY Preferred Stock The Company is authorized to issue up to 5,000,000 shares of preferred stock with rights and preferences as may September 30, 2021 December 31, 2020. Common Stock April 2020 In the second 2020, 2020 8 April 27, 2020 September 15, 2020. second 2020, 2020 May 2021 In the second 2021, 2021 8 May 14, 2021. second 2021, 2021 Common Stock Warrants July 2011 In the third 2011, “July 2011 July 2011 July 5, 2016. October 2015, July 2011 March 6, 2020. February 2016 May 2019, July 2011 In March 2020, July 2011 September 30, 2021, July 2011 March 2015 In the first 2015, “March 2015 March 2015 March 2015 March 6, 2020 March 2015 September 6, 2015. October 2015, March 2015 September 6, 2015 March 6, 2020. February 2016 May 2019, July 2011 During the first 2020, March 2015 first 2020, March 2015 September 30, 2021, March 2015 October 2015 In the fourth 2015, “October 2015 October 27, 2020. February 2016 May 2019, October 2015 fourth 2020, October 2015 During the fourth 2020, October 2015 September 30, 2021, October 2015 June 2019 June 2019 During the second 2019, “June 2019 six The June 2019 June 17, 2020. June 2019 During the first 2020, June 2019 six During the second 2020, June 2019 six second 2020, June 2019 September 30, 2021, June 2019 August 2019 2019 2019 2019 In the third 2019, “2019 “2019 2019 February 13, 2025. The Company allocated the proceeds between the common stock and 2019 first 2019 11, 2019 Ladenburg served as the placement agent for the transaction in exchange for a commission representing six August 8, 2024 ( “2019 The Company incurred total issuance costs of $0.5 million in conjunction with the 2019 2019 11, 2019 During the third 2020, 2019 2019 six 2019 During the third 2020, 2019 2019 2019 2019 1 2019 2019 2 100% 2019 2019 The New Warrants became exercisable nine five 2019 2019 one not During the third 2020, 2019 11, 2019 no TLF Bio Innovation 2021 On January 15, 2021, five The details of all outstanding warrants as of September 30, 2021 Warrants (in thousands) Weighted- Average Exercise Price Outstanding at December 31, 2020 7,067 $ 1.63 Warrants granted 15 $ 0.67 Warrants exercised — $ — Warrants expired — $ — Outstanding at September 30, 2021 7,082 $ 1.63 |
Note 13 - Equity-based Compensa
Note 13 - Equity-based Compensation | 9 Months Ended |
Sep. 30, 2021 | |
Notes to Financial Statements | |
Share-based Payment Arrangement [Text Block] | NOTE 13. Equity Compensation Plans In October 2007, 2007 “2007 2007 March 15, 2017. 2007 2007 no ten 2007 December 31, 2020. In March 2017, 2017 “2017 June 2, 2017, 2017 not 2007 2017 first January 1, 2018 January 1, 2027 4 2017 January 15, 2021, 2017 September 30, 2021, 2017 Under the terms of the 2017 may not not not ten not five 10% four 2007 2017 Stock Option Summary The following table summarizes information about the Company’s stock options and restricted stock outstanding at September 30, 2021 September 30, 2021 : (in thousands, except years and per share data) Options Weighted- Average Exercise Price Weighted- Average Remaining Contractual Life (years) Aggregate Intrinsic Value Outstanding at December 31, 2020 3,165 $ 2.05 7.6 $ 189 Options granted 291 $ 0.74 Restricted stock units granted 1,228 $ — Options exercised - $ — Restricted stock units vested (488 ) $ — Options forfeited/cancelled (249 ) $ 2.39 Restricted stock units cancelled - $ — Outstanding at September 30, 2021 3,947 $ 1.54 7.6 $ 633 Vested and expected to vest at September 30, 2021 3,601 $ 1.64 7.4 $ 562 Vested at September 30, 2021 1,802 $ 2.77 5.6 $ 34 Exercisable at September 30, 2021 1,802 $ 2.77 5.6 $ 34 The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying stock option awards and the closing market price of the Company’s common stock as quoted on the NYSE American as of September 30, 2021 three nine September 30, 2021. three nine September 30, 2021. three nine September 30, 2020, As of September 30, 2021, Stock Option Awards to Employees and Directors The Company grants options to purchase common stock to its employees and directors at prices equal to or greater than the market value of the stock on the dates the options are granted. The Company has estimated the value of stock option awards as of the date of grant by applying the Black-Scholes option pricing model using the single-option valuation approach. The application of this valuation model involves assumptions that are judgmental and subjective in nature. See Note 2, During the nine September 30, 2021 2020, The weighted-average assumptions used in determining the value of options are as follows: Nine Months Ended September 30, Assumption 2021 2020 Expected price volatility 163.95 % 160.57 % Expected term (in years) 6.19 6.45 Risk-free interest rate 0.92 % 0.45 % Dividend yield 0.00 % 0.00 % Weighted-average fair value of options granted during the period $ 0.71 $ 0.94 Expected Price Volatility Expected Term Risk-Free Interest Rate Dividend Yield not Forfeitures are estimated at the time of grant and reduce compensation expense ratably over the vesting period. This estimate is adjusted periodically based on the extent to which actual forfeitures differ, or are expected to differ, from the previous estimate. In addition, during the nine September 30, 2021, nine September 30, 2020, For the three September 30, 2021 2020, nine September 30, 2021 2020, In April 2020, April 1, 2020. three three In August 2020, August 21, 2020. three three Stock-Based Awards to Non-Employees During the nine September 30, 2021, not nine September 30, 2020, The stock options are recorded at their fair value on the grant date and recognized over the respective service or vesting period. The fair value of the stock options that are granted is calculated using the Black-Scholes-Merton option pricing model based upon the following assumptions: Nine Months Ended September 30, Assumption 2020 Expected price volatility 162.30 % Expected term (in years) 6.34 Risk-free interest rate 0.33 % Dividend yield 0.00 % Weighted-average fair value of options granted during the period $ 1.27 For the three September 30, 2021 2020, nine September 30, 2021 2020, In connection with Mr. Mark Sieczkarek’s resignation in 2019, two 2017 two July 1, 2020 July 1, 2021, July 2020, July 2021, Summary of Stock-Based Compensation Expense A summary of the stock-based compensation expense included in results of operations for the options and restricted stock awards discussed above is as follows (in thousands): Three Months Ended September 30, Nine Months Ended September 30, (in thousands) 2021 2020 2021 2020 Research and development $ 2 $ 8 $ 8 $ 22 Sales and Marketing 53 29 118 49 General and administrative 169 139 576 288 Total stock-based compensation expense $ 224 $ 176 $ 702 $ 359 |
Note 14 - License, Collaboratio
Note 14 - License, Collaboration and Distribution Agreements | 9 Months Ended |
Sep. 30, 2021 | |
Notes to Financial Statements | |
License, Collaboration, and Distribution Agreements [Text Block] | NOTE 14. Transactions under the Company’s major distribution agreements are recognized upon transfer of control of product sold to its major distribution partners at the amount of consideration that the Company expects to be entitled to. The Company records contract liabilities for the amounts that are estimated to be subject to significant reversal, including allowances for services, discounts, rebate programs, and product returns. The following table presents changes in the Company's contract assets and liabilities for the nine September 30, 2021 ( Balance at December 31, 2020 Additions Deductions Balance at September 30, 2021 Contract Liabilities: Deferred Revenue $ 2 $ 122 $ (2 ) $ 122 Contract Liabilities: Accrued Liabilities (includes contract assets) 573 1,213 (1,250 ) 536 Total $ 575 $ 1,335 $ (1,252 ) $ 658 During the nine September 30, 2021 2020, Nine Months Ended September 30, 2021 2020 Revenue recognized in the period from: Amounts included in contract liabilities at the beginning of the period: Performance obligations satisfied $ 573 $ 434 New activities in the period: Performance obligations satisfied 5,207 7,612 $ 5,780 $ 8,046 Avenova Distribution Agreements and Specialty Pharmacies Prescription Avenova is made available in local pharmacies and major pharmacy retail chains under nationwide distribution agreements with McKesson Corporation, Cardinal Health and AmerisourceBergen. We have also entered into direct agreements with preferred pharmacy networks as part of our Partner Pharmacy Program. During the three September 30, 2021 2020, nine September 30, 2021 2020, Under the prescription Avenova product distribution arrangements, the Company had a contract liability balance of $0.6 million and $0.7 million at September 30, 2021 December 31, 2020, September 30, 2021 December 31, 2020, 4, Over-the-counter Avenova Non-prescription Avenova was launched online on September 1, 2019 three nine September 30, 2021, three nine September 30, 2020, |
Note 15 - Employee Benefit Plan
Note 15 - Employee Benefit Plan | 9 Months Ended |
Sep. 30, 2021 | |
Notes to Financial Statements | |
Retirement Benefits [Text Block] | NOTE 15. The Company has a 401 not three nine September 30, 2021 2020. 401 January 1, 2022, |
Note 16 - Related Party Transac
Note 16 - Related Party Transactions | 9 Months Ended |
Sep. 30, 2021 | |
Notes to Financial Statements | |
Related Party Transactions Disclosure [Text Block] | NOTE 16. Related Party Revenue The following table summarizes information about the Company’s related party revenue and cost of goods sold during the three nine September 30, 2021 2020, Three Months Ended September 30, Nine Months Ended September 30, (in thousands) 2021 2020 2021 2020 Related party revenue: NeutroPhase $ — $ — $ 175 $ 173 Total related party revenue $ — $ — $ 175 $ 173 Cost of goods sold: NeutroPhase $ — $ — $ 131 $ 90 Total related party expenses $ — $ — $ 131 $ 90 Related party accounts receivable was $0.1 million and $0.2 million as of September 30, 2021 December 31, 2020, Other Related Party Expenses During the nine September 30, 2021 December 31, 2020, KN95 September 30, 2021 December 31, 2020, The following table summarizes information about the Company’s other related party expenses excluding stock-based compensation during the three nine September 30, 2021 2020, Three Months Ended September 30, Nine Months Ended eptember 30, 2021 2020 2021 2020 Commissions to China Kington related to: Exercise of 2019 Foreign Warrants $ — $ 160 $ — $ 160 Exercise of June Warrants — — — 41 Total commissions to China Kington — 160 — 201 Board Director Bob Wu consulting fee — — — 50 Total related party expenses $ — $ 160 $ — $ 251 In connection with the Company's re-launch of CelleRx Clinical Reset, on November 17, 2020, twelve 2017 one three nine September 30, 2020 three nine September 30, 2021, |
Note 17 - Paycheck Protection P
Note 17 - Paycheck Protection Program | 9 Months Ended |
Sep. 30, 2021 | |
COVID 19 Member [Member] | |
Notes to Financial Statements | |
Unusual or Infrequent Items, or Both, Disclosure [Text Block] | NOTE 17. On May 6, 2020, March 27, 2020.The 2020, September 5, 2020. 1.00% two 2021. no 24 Since the Company determined that there was reasonable assurance that it would meet the conditions for forgiveness of the full loan amount, the Company accounted for the forgivable PPP Loan as a government income grant that we earned through the Company’s compliance with the loan forgiveness criteria. A deferred income liability was recognized upon receipt of the forgivable loan proceeds. The deferred income liability was recognized as other income as Qualifying Expenses were incurred. For the three nine September 30, 2020, No three nine September 30, 2021. The Company received notice, dated May 24, 2021, |
Note 18 - Dermadoctor Llc Acqui
Note 18 - Dermadoctor Llc Acquisition | 9 Months Ended |
Sep. 30, 2021 | |
Notes to Financial Statements | |
Business Combination Disclosure [Text Block] | NOTE 18. On September 27, 2021, 1998 30 The Closing was subject to certain conditions, including the Company completing a financing to raise capital sufficient to fund the purchase price for the Transaction, which the Company completed in the fourth 2021 19, |
Note 19 - Subsequent Events
Note 19 - Subsequent Events | 9 Months Ended |
Sep. 30, 2021 | |
Notes to Financial Statements | |
Subsequent Events [Text Block] | NOTE 19. On October 29, 2021, November 2, 2021. On November 5, 2021, 18, |
Significant Accounting Policies
Significant Accounting Policies (Policies) | 9 Months Ended |
Sep. 30, 2021 | |
Accounting Policies [Abstract] | |
Basis of Accounting, Policy [Policy Text Block] | Basis of Presentation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) and are expressed in U.S. dollars. |
Use of Estimates, Policy [Policy Text Block] | Use of Estimates The preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. These estimates include contract liabilities related to product sales, useful lives for property and equipment and related depreciation calculations, assumptions for valuing options and warrants, income taxes and other contingencies. Actual results could differ from those estimates. |
Unaudited Interim Financial Information, Policy [Policy Text Block] | Unaudited Interim Financial Information The accompanying unaudited interim condensed consolidated financial statements and related disclosures have been prepared on the same basis as the annual consolidated financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary for a fair statement of the results of operations for the periods presented. The year-end condensed consolidated balance sheet data was derived from audited financial statements but does not not The financial statements and notes included herein should be read in conjunction with the annual financial statements and notes for the year ended December 31, 2020, 10 December 31, 2020, March 25, 2021. |
Cash and Cash Equivalents, Policy [Policy Text Block] | Cash, Cash Equivalents, and Restricted Cash The Company considers all highly-liquid instruments with a stated maturity of three September 30, 2021 December 31, 2020, The following table provides a reconciliation of the cash, cash equivalents, and restricted cash reported in the condensed consolidated balance sheets that sum to the total of the same reported in the condensed consolidated statements of cash flows (in thousands): September 30, December 31, 2021 2020 Cash and cash equivalents $ 9,028 $ 11,952 Restricted cash included in other assets 475 475 Total cash, cash equivalents, and restricted cash in the condensed consolidated statements of cash flows $ 9,503 $ 12,427 The restricted cash amount included in other assets on the condensed consolidated balance sheets represents amounts held as certificates of deposit for Company credit cards and lease arrangements as contractually required by our financial institution and landlord. |
Concentration Risk, Credit Risk, Policy [Policy Text Block] | Concentrations of Credit Risk and Major Partners Financial instruments that potentially subject us to significant concentrations of credit risk consist primarily of cash, cash equivalents and restricted cash. The Company maintains deposits of cash, cash equivalents and restricted cash with a highly-rated, major financial institution in the United States. Deposits in this bank may not During the three nine September 30, 2021 2020, nine 2020, second KN95 During the three nine September 30, 2021 2020, Three Months Ended September 30, Nine months Ended September 30, 2021 2020 2021 2020 Avenova $ 1,763 $ 1,835 $ 5,221 $ 4,509 KN95 Masks — 69 — 3,081 Other products 71 263 540 448 Total product revenue, net 1,834 2,167 5,761 8,038 Other revenue, net 6 3 19 8 Total sales, net $ 1,840 $ 2,170 $ 5,780 $ 8,046 During the three September 30, 2021 2020, nine September 30, 2021 2020, No 10% three nine September 30, 2021 2020. As of September 30, 2021 December 31, 2020, 10% September 30, December 31, Major distribution partner 2021 2020 Avenova Direct via Amazon 26 % 11 % Distributor A 18 % 18 % Distributor B 16 % 14 % Chongqing Pioneer Pharma Holdings Limited 15 % 16 % Distributor C * % 14 % *Not greater than 10% The Company relies on two not third may may not may 19 |
Fair Value of Financial Instruments, Policy [Policy Text Block] | Fair Value of Financial Assets and Liabilities The Company’s financial instruments include cash and cash equivalents, restricted cash, accounts receivable, accounts payable, and accrued liabilities. The Company’s cash and cash equivalents, accounts receivable, accounts payable, and accrued liabilities are carried at cost, which management believes approximates fair value due to the short-term nature of these instruments. The Company follows Accounting Standards Codification (“ASC”) 820, Fair Value Measurements and Disclosures three may Level 1 Level 2 Level 3 Categorization within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement. |
Receivables, Trade and Other Accounts Receivable, Allowance for Doubtful Accounts, Policy [Policy Text Block] | Allowance for Doubtful Accounts The Company charges bad debt expense and records an allowance for doubtful accounts when management believes it to be unlikely that specific invoices will be collected. Management identifies amounts due that are in dispute and it believes are unlikely to be collected. At September 30, 2021 December 31, 2020, |
Inventory, Policy [Policy Text Block] | Inventory Inventory is comprised of ( 1 2 3 first first September 30, 2021 December 31, 2020, |
Property, Plant and Equipment, Policy [Policy Text Block] | Property and Equipment Property and equipment are stated at cost, less accumulated depreciation and amortization. Depreciation is calculated using the straight-line method over the estimated useful lives of the related assets of five seven three seven The costs of normal maintenance, repairs, and minor replacements are expensed as incurred. |
Lessee, Leases [Policy Text Block] | Leases At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present. Operating lease liabilities and their corresponding right-of-use assets are recorded based on the present value of lease payments over the expected lease term. The interest rate implicit in lease contracts is typically not may The Company has elected to combine lease and non-lease components as a single component for all leases in which it is a lessee or a lessor. The lease expense is recognized over the expected term on a straight-line basis. Operating leases are recognized on the balance sheet as right-of-use assets, operating lease liabilities current and operating lease liabilities non-current. As a result, as of the effective date, the Company no |
Comprehensive Income, Policy [Policy Text Block] | Comprehensive Income (Loss) ASC 220, Comprehensive Income, |
Revenue from Contract with Customer [Policy Text Block] | Revenue Recognition Revenue generated through the Company’s webstores, Avenova.com and CelleRx.com, for Avenova and CelleRx (as well as the KN95 third Revenue generated through Amazon.com and Walmart.com third The Company also generates Avenova product revenue through product sales to its major distribution partners. Product supply of Avenova is the only performance obligation contained in these arrangements, and the Company recognizes product revenue upon transfer of control to its major distribution partners at the amount of consideration that the Company expects to be entitled to, generally upon receipt by the distributor on a “sell-in” basis. Upon recognition of product sales, contract liabilities are recorded for invoiced amounts that are subject to significant reversal, including product revenue allowances for cash consideration paid to customers for services, discounts, rebate programs, and product returns. The Company derives its rate of return from historical data and updates its return rate assumption quarterly. Payment for product supply is typically due 30 Revenue generated through the Company’s partner pharmacies is recognized when control of the product transfers to the end customer. Revenue for product sales to CVS is recognized upon transfer of control to CVS, which generally occurs upon delivery of the related products to a third |
Cost of Goods Sold, Policy [Policy Text Block] | Cost of Goods Sold Cost of goods sold includes third |
Research and Development Expense, Policy [Policy Text Block] | Research and Development Costs The Company charges research and development costs to expense as incurred. These costs include all costs associated with research, development and regulatory activities, including submissions to the Food and Drug Administration (“FDA”). |
Patent Costs Policy [Policy Text Block] | Patent Costs Patent costs, including legal expenses, are expensed in the period in which they are incurred. Patent expenses are included in general and administrative expenses in the condensed consolidated statements of operations and comprehensive loss. |
Advertising Cost [Policy Text Block] | Advertising Costs Advertising costs are expensed in the period in which the costs are incurred. Advertising expenses were $0.8 million and $0.5 million for the three September 30, 2021 2020, nine September 30, 2021 2020, |
Share-based Payment Arrangement [Policy Text Block] | Stock-Based Compensation The Company’s stock-based compensation includes grants of stock options and restricted stock units (“RSUs”) to employees, consultants and non-employee directors. The expense associated with these grants is recognized in the Company’s condensed consolidated statements of stockholders’ equity (deficit) based on their fair values as they are earned under the applicable vesting terms. For stock options granted, the fair value of the stock options is estimated using a Black-Scholes option pricing model. See Note 13, |
Income Tax, Policy [Policy Text Block] | Income Taxes The Company accounts for income taxes under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is recognized if it is more likely than not not |
Warrant Liabilities [Policy Text Block] | Common Stock Warrant Liability The Company accounts for common stock purchase warrants issued in connection with its equity offerings in accordance with the provisions of ASC 480, Distinguishing Liabilities from Equity 815, Derivatives and Hedging The Company accounts for common stock purchase warrants issued in connection with share-based compensation arrangements in accordance with the provisions of ASC 718, Stock Compensation, 480, Distinguishing Liabilities from Equity The Company classifies as equity any contracts that (i) require physical settlement or net-share settlement or (ii) give the Company a choice of net-cash settlement or settlement in its own shares (physical settlement or net-share settlement). The Company classifies as assets or liabilities any contracts that (i) require net-cash settlement (including a requirement to net-cash settle the contract if an event occurs and if that event is outside the control of the Company) or (ii) give the counterparty a choice of net-cash settlement or settlement in shares (physical settlement or net-share settlement). Additionally, for common stock purchase warrants accounted for in accordance with ASC 718, Stock Compensation, For warrants that are classified as liabilities, the Company records the fair value of the warrants at each balance sheet date and records changes in the estimated fair value as a non-cash gain or loss in the consolidated statements of operations and comprehensive loss. The fair values of these warrants are determined using the Black-Scholes option pricing model, the Binomial Lattice (“Lattice”) valuation model, or the Monte Carlo simulation model where deemed appropriate. These values are subject to a significant degree of management’s judgment. |
Earnings Per Share, Policy [Policy Text Block] | Net Loss Per Share The Company computes net loss per share by presenting both basic and diluted earnings (loss) per share (“EPS”). Basic EPS is computed by dividing net loss available to common stockholders by the weighted average number of common shares outstanding during the period. Diluted EPS gives effect to all dilutive potential common shares outstanding during the period, including stock options and warrants, using the treasury stock method. In computing diluted EPS, the average stock price for the period is used to determine the number of shares assumed to be purchased from the exercise of stock options or warrants. Potentially dilutive common share equivalents are excluded from the diluted EPS computation in net loss periods because their effect would be anti-dilutive. We have incurred a net loss for all periods presented in the unaudited condensed consolidated statements of operations and comprehensive loss. The following common stock equivalents were not As of September 30, 2021 2020 Stock options 3,947 3,328 Stock warrants 7,082 7,067 11,029 10,395 |
New Accounting Pronouncements, Policy [Policy Text Block] | Recent Accounting Pronouncements For information regarding recent accounting pronouncements that could affect our business, results of operations, financial condition, and liquidity, see Note 2, 10 December 31, 2020, March 25, 2021. no |
Note 2 - Summary of Significa_2
Note 2 - Summary of Significant Accounting Policies (Tables) | 9 Months Ended |
Sep. 30, 2021 | |
Notes Tables | |
Schedule of Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Table Text Block] | September 30, December 31, 2021 2020 Cash and cash equivalents $ 9,028 $ 11,952 Restricted cash included in other assets 475 475 Total cash, cash equivalents, and restricted cash in the condensed consolidated statements of cash flows $ 9,503 $ 12,427 |
Schedules of Concentration of Risk, by Product [Table Text Block] | Three Months Ended September 30, Nine months Ended September 30, 2021 2020 2021 2020 Avenova $ 1,763 $ 1,835 $ 5,221 $ 4,509 KN95 Masks — 69 — 3,081 Other products 71 263 540 448 Total product revenue, net 1,834 2,167 5,761 8,038 Other revenue, net 6 3 19 8 Total sales, net $ 1,840 $ 2,170 $ 5,780 $ 8,046 |
Schedules of Concentration of Risk, by Risk Factor [Table Text Block] | September 30, December 31, Major distribution partner 2021 2020 Avenova Direct via Amazon 26 % 11 % Distributor A 18 % 18 % Distributor B 16 % 14 % Chongqing Pioneer Pharma Holdings Limited 15 % 16 % Distributor C * % 14 % *Not greater than 10% |
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] | As of September 30, 2021 2020 Stock options 3,947 3,328 Stock warrants 7,082 7,067 11,029 10,395 |
Note 3 - Fair Value Measureme_2
Note 3 - Fair Value Measurements (Tables) | 9 Months Ended |
Sep. 30, 2021 | |
Notes Tables | |
Fair Value, Assets Measured on Recurring Basis [Table Text Block] | Fair Value Measurements Using Assets Balance at September 30, 2021 Quoted Prices in Active Markets for Identical Items (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Restricted cash held as a certificate of deposit $ 324 $ 324 $ — $ — Deposit held as a certificate of deposit 151 151 — — Total assets $ 475 $ 475 $ — $ — Fair Value Measurements Using Assets Balance at December 31, 2020 Quoted Prices in Active Markets for Identical Items (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Restricted cash held as a certificate of deposit $ 324 $ 324 $ — $ — Deposit held as a certificate of deposit 151 151 — — Total assets $ 475 $ 475 $ — $ — |
Note 4 - Prepaid Expenses and_2
Note 4 - Prepaid Expenses and Other Current Assets (Tables) | 9 Months Ended |
Sep. 30, 2021 | |
Notes Tables | |
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block] | September 30, December 31, 2021 2020 Prepaid inventory $ 214 $ — Prepaid insurance 150 165 Prepaid financing costs 104 — Prepaid sales rebates (Avenova contract asset) 44 144 Prepaid dues and subscriptions 18 53 Prepaid patents 10 47 Prepaid security deposit for lease — 65 Other 117 102 Total prepaid expenses and other current assets $ 657 $ 576 |
Note 5 - Inventory (Tables)
Note 5 - Inventory (Tables) | 9 Months Ended |
Sep. 30, 2021 | |
Notes Tables | |
Schedule of Inventory, Current [Table Text Block] | September 30, December 31, 2021 2020 Raw materials and supplies $ 271 $ 159 Finished goods 847 685 Less: Reserve for excess and obsolete inventory (149 ) (236 ) Total inventory, net $ 969 $ 608 |
Note 6 - Property and Equipme_2
Note 6 - Property and Equipment (Tables) | 9 Months Ended |
Sep. 30, 2021 | |
Notes Tables | |
Property, Plant and Equipment [Table Text Block] | September 30, December 31, 2021 2020 Computer equipment and software $ 409 $ 365 Furniture and fixtures 157 157 Leasehold improvements 79 79 Production equipment 65 65 Office equipment 20 20 Total property and equipment, at cost 730 686 Less: accumulated depreciation and amortization (634 ) (602 ) Total property and equipment, net $ 96 $ 84 |
Note 7 - Accrued Liabilities (T
Note 7 - Accrued Liabilities (Tables) | 9 Months Ended |
Sep. 30, 2021 | |
Notes Tables | |
Schedule of Accrued Liabilities [Table Text Block] | September 30, December 31, 2021 2020 Avenova contract liabilities $ 579 $ 730 Employee payroll and benefits 396 632 Sublease security deposit — 198 Inventory purchases — 181 Consulting services — 98 Other 350 276 Total accrued liabilities $ 1,325 $ 2,115 |
Note 8 - Commitments and Cont_2
Note 8 - Commitments and Contingencies (Tables) | 9 Months Ended |
Sep. 30, 2021 | |
Notes Tables | |
Lease, Cost [Table Text Block] | Lease Costs Three Months Ended September 30, Nine months Ended September 30, 2021 2020 2021 2020 Operating lease cost $ 99 $ 212 $ 298 $ 726 Sublease income — (105 ) — (421 ) Net lease cost $ 99 $ 107 $ 298 $ 305 Other information Operational cash flow used for operating leases $ 113 $ 236 $ 339 $ 816 September 30, 2021 September 30, 2020 Weighted-average remaining lease term (in years) 0.5 1.5 Weighted-average discount rate 12 % 12 % |
Lessee, Operating Lease, Liability, Maturity [Table Text Block] | 2021 $ 114 2022 88 Total future minimum lease payments 202 Less imputed interest (6 ) Total $ 196 Reported as: Operating lease liability $ 195 Operating lease liability- non-current 1 Total $ 196 |
Note 11 - Warrant Liability (Ta
Note 11 - Warrant Liability (Tables) | 9 Months Ended |
Sep. 30, 2021 | |
Notes Tables | |
Schedule of Derivative Instruments [Table Text Block] | Assumptions 2019 Domestic Warrants 2019 Foreign Warrants Expected price volatility 178 % 178 % Expected term (in years) 4.57 4.57 Risk-free interest rate 0.25 % 0.27 % Dividend yield 0.00 % 0.00 % Weighted-average fair value of warrant $ 1.18 $ 1.54 Expected price volatility 186 % Expected term (in years) 4.05 Risk-free interest rate 0.22 % Dividend yield 0.00 % Weighted-average fair value of warrants $ 1.17 |
Note 12 - Stockholders' Equity
Note 12 - Stockholders' Equity (Tables) | 9 Months Ended |
Sep. 30, 2021 | |
Notes Tables | |
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block] | Warrants (in thousands) Weighted- Average Exercise Price Outstanding at December 31, 2020 7,067 $ 1.63 Warrants granted 15 $ 0.67 Warrants exercised — $ — Warrants expired — $ — Outstanding at September 30, 2021 7,082 $ 1.63 |
Note 13 - Equity-based Compen_2
Note 13 - Equity-based Compensation (Tables) | 9 Months Ended |
Sep. 30, 2021 | |
Notes Tables | |
Share-based Payment Arrangement, Option, Activity [Table Text Block] | (in thousands, except years and per share data) Options Weighted- Average Exercise Price Weighted- Average Remaining Contractual Life (years) Aggregate Intrinsic Value Outstanding at December 31, 2020 3,165 $ 2.05 7.6 $ 189 Options granted 291 $ 0.74 Restricted stock units granted 1,228 $ — Options exercised - $ — Restricted stock units vested (488 ) $ — Options forfeited/cancelled (249 ) $ 2.39 Restricted stock units cancelled - $ — Outstanding at September 30, 2021 3,947 $ 1.54 7.6 $ 633 Vested and expected to vest at September 30, 2021 3,601 $ 1.64 7.4 $ 562 Vested at September 30, 2021 1,802 $ 2.77 5.6 $ 34 Exercisable at September 30, 2021 1,802 $ 2.77 5.6 $ 34 |
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] | Three Months Ended September 30, Nine Months Ended September 30, (in thousands) 2021 2020 2021 2020 Research and development $ 2 $ 8 $ 8 $ 22 Sales and Marketing 53 29 118 49 General and administrative 169 139 576 288 Total stock-based compensation expense $ 224 $ 176 $ 702 $ 359 |
Nonemployees [Member] | |
Notes Tables | |
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] | Nine Months Ended September 30, Assumption 2020 Expected price volatility 162.30 % Expected term (in years) 6.34 Risk-free interest rate 0.33 % Dividend yield 0.00 % Weighted-average fair value of options granted during the period $ 1.27 |
Employees and Directors [Member] | |
Notes Tables | |
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] | Nine Months Ended September 30, Assumption 2021 2020 Expected price volatility 163.95 % 160.57 % Expected term (in years) 6.19 6.45 Risk-free interest rate 0.92 % 0.45 % Dividend yield 0.00 % 0.00 % Weighted-average fair value of options granted during the period $ 0.71 $ 0.94 |
Note 14 - License, Collaborat_2
Note 14 - License, Collaboration and Distribution Agreements (Tables) | 9 Months Ended |
Sep. 30, 2021 | |
Notes Tables | |
Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block] | Balance at December 31, 2020 Additions Deductions Balance at September 30, 2021 Contract Liabilities: Deferred Revenue $ 2 $ 122 $ (2 ) $ 122 Contract Liabilities: Accrued Liabilities (includes contract assets) 573 1,213 (1,250 ) 536 Total $ 575 $ 1,335 $ (1,252 ) $ 658 |
Disaggregation of Revenue [Table Text Block] | Nine Months Ended September 30, 2021 2020 Revenue recognized in the period from: Amounts included in contract liabilities at the beginning of the period: Performance obligations satisfied $ 573 $ 434 New activities in the period: Performance obligations satisfied 5,207 7,612 $ 5,780 $ 8,046 |
Note 16 - Related Party Trans_2
Note 16 - Related Party Transactions (Tables) | 9 Months Ended |
Sep. 30, 2021 | |
Notes Tables | |
Schedule of Related Party Transactions [Table Text Block] | Three Months Ended September 30, Nine Months Ended September 30, (in thousands) 2021 2020 2021 2020 Related party revenue: NeutroPhase $ — $ — $ 175 $ 173 Total related party revenue $ — $ — $ 175 $ 173 Cost of goods sold: NeutroPhase $ — $ — $ 131 $ 90 Total related party expenses $ — $ — $ 131 $ 90 Three Months Ended September 30, Nine Months Ended eptember 30, 2021 2020 2021 2020 Commissions to China Kington related to: Exercise of 2019 Foreign Warrants $ — $ 160 $ — $ 160 Exercise of June Warrants — — — 41 Total commissions to China Kington — 160 — 201 Board Director Bob Wu consulting fee — — — 50 Total related party expenses $ — $ 160 $ — $ 251 |
Note 2 - Summary of Significa_3
Note 2 - Summary of Significant Accounting Policies (Details Textual) - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | |||
Sep. 30, 2021 | Sep. 30, 2020 | Sep. 30, 2021 | Sep. 30, 2020 | Dec. 31, 2020 | |
Accounts Receivable, Allowance for Credit Loss, Ending Balance | $ 0 | $ 0 | $ 0 | ||
Inventory Valuation Reserves, Ending Balance | 149 | 149 | $ 236 | ||
Advertising Expense | $ 800 | $ 500 | $ 2,300 | $ 1,300 | |
Equipment [Member] | Minimum [Member] | |||||
Property, Plant and Equipment, Useful Life (Year) | 5 years | ||||
Equipment [Member] | Maximum [Member] | |||||
Property, Plant and Equipment, Useful Life (Year) | 7 years | ||||
Computer Equipment and Software [Member] | |||||
Property, Plant and Equipment, Useful Life (Year) | 3 years | ||||
Furniture and Fixtures [Member] | |||||
Property, Plant and Equipment, Useful Life (Year) | 7 years | ||||
Revenue from Contract with Customer Benchmark [Member] | Distributor Concentration Risk [Member] | Avenova Product [Member] | |||||
Concentration Risk, Percentage | 55.00% | 47.00% | 57.00% | 46.00% |
Note 2 - Summary of Significa_4
Note 2 - Summary of Significant Accounting Policies - Components of Cash, Cash Equivalents, and Restricted Cash (Details) - USD ($) $ in Thousands | Sep. 30, 2021 | Dec. 31, 2020 | Sep. 30, 2020 | Dec. 31, 2019 |
Cash and cash equivalents | $ 9,028 | $ 11,952 | ||
Restricted cash included in other assets | 475 | 475 | ||
Total cash, cash equivalents, and restricted cash in the condensed consolidated statements of cash flows | $ 9,503 | $ 12,427 | $ 13,888 | $ 7,412 |
Note 2 - Summary of Significa_5
Note 2 - Summary of Significant Accounting Policies - Disaggregation of Revenue (Details) - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | |||
Sep. 30, 2021 | Sep. 30, 2020 | Sep. 30, 2021 | Sep. 30, 2020 | Sep. 30, 2020 | |
Total sales, net | $ 1,840 | $ 2,170 | $ 5,780 | $ 8,046 | $ 8,046 |
Avenova Product [Member] | |||||
Total sales, net | 1,763 | 1,835 | 5,221 | 4,509 | |
KN95 Masks [Member] | |||||
Total sales, net | 0 | 69 | 0 | 3,081 | |
Other Products [member] | |||||
Total sales, net | 71 | 263 | 540 | 448 | |
Product [Member] | |||||
Total sales, net | 1,834 | 2,167 | 5,761 | 8,038 | 8,038 |
Product and Service, Other [Member] | |||||
Total sales, net | $ 6 | $ 3 | $ 19 | $ 8 | $ 8 |
Note 2 - Summary of Significa_6
Note 2 - Summary of Significant Accounting Policies - Revenues and Accounts Receivable From Major Distribution Partners and Customers (Details) - Customer Concentration Risk [Member] - Accounts Receivable [Member] | 9 Months Ended | 12 Months Ended |
Sep. 30, 2021 | Dec. 31, 2020 | |
Avenova via Amazon [Member] | ||
Distribution or collaboration partners | 26.00% | 11.00% |
Distributor A [Member] | ||
Distribution or collaboration partners | 18.00% | 18.00% |
Distributor B [Member] | ||
Distribution or collaboration partners | 16.00% | 14.00% |
Chongqing Pioneer Pharma Holdings Limited [Member] | ||
Distribution or collaboration partners | 15.00% | 16.00% |
Distributor C [Member] | ||
Distribution or collaboration partners | 14.00% |
Note 2 - Summary of Significa_7
Note 2 - Summary of Significant Accounting Policies - Outstanding Stock Options and Stock Warrants Excluded From the Diluted Net Loss Per Share Computation (Details) - shares shares in Thousands | 9 Months Ended | |
Sep. 30, 2021 | Sep. 30, 2020 | |
Anti-dilutive securities (in shares) | 11,029 | 10,395 |
Share-based Payment Arrangement, Option [Member] | ||
Anti-dilutive securities (in shares) | 3,947 | 3,328 |
Warrant [Member] | ||
Anti-dilutive securities (in shares) | 7,082 | 7,067 |
Note 3 - Fair Value Measureme_3
Note 3 - Fair Value Measurements - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details) - Fair Value, Recurring [Member] - USD ($) $ in Thousands | Sep. 30, 2021 | Dec. 31, 2020 |
Restricted cash held as a certificate of deposit | $ 324 | $ 324 |
Deposit held as a certificate of deposit | 151 | 151 |
Total assets | 475 | 475 |
Fair Value, Inputs, Level 1 [Member] | ||
Restricted cash held as a certificate of deposit | 324 | 324 |
Deposit held as a certificate of deposit | 151 | 151 |
Total assets | 475 | 475 |
Fair Value, Inputs, Level 2 [Member] | ||
Restricted cash held as a certificate of deposit | 0 | 0 |
Deposit held as a certificate of deposit | 0 | 0 |
Total assets | 0 | 0 |
Fair Value, Inputs, Level 3 [Member] | ||
Restricted cash held as a certificate of deposit | 0 | 0 |
Deposit held as a certificate of deposit | 0 | 0 |
Total assets | $ 0 | $ 0 |
Note 4 - Prepaid Expenses and_3
Note 4 - Prepaid Expenses and Other Current Assets - Summary of Prepaid Expenses and Other Current Assets (Details) - USD ($) $ in Thousands | Sep. 30, 2021 | Dec. 31, 2020 |
Prepaid inventory | $ 214 | $ 0 |
Prepaid insurance | 150 | 165 |
Prepaid financing costs | 104 | 0 |
Prepaid sales rebates (Avenova contract asset) | 44 | 144 |
Prepaid dues and subscriptions | 18 | 53 |
Prepaid patents | 10 | 47 |
Prepaid security deposit for lease | 0 | 65 |
Other | 117 | 102 |
Total prepaid expenses and other current assets | $ 657 | $ 576 |
Note 5 - Inventory - Summary of
Note 5 - Inventory - Summary of Inventory (Details) - USD ($) $ in Thousands | Sep. 30, 2021 | Dec. 31, 2020 |
Raw materials and supplies | $ 271 | $ 159 |
Finished goods | 847 | 685 |
Less: Reserve for excess and obsolete inventory | (149) | (236) |
Total inventory, net | $ 969 | $ 608 |
Note 6 - Property and Equipme_3
Note 6 - Property and Equipment (Details Textual) - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2021 | Sep. 30, 2020 | Sep. 30, 2021 | Sep. 30, 2020 | |
Depreciation, Depletion and Amortization, Total | $ 13 | $ 12 | $ 32 | $ 40 |
Note 6 - Property and Equipme_4
Note 6 - Property and Equipment - Summary of Property and Equipment (Details) - USD ($) $ in Thousands | Sep. 30, 2021 | Dec. 31, 2020 |
Property and equipment, at cost | $ 730 | $ 686 |
Less: accumulated depreciation and amortization | (634) | (602) |
Total property and equipment, net | 96 | 84 |
Computer Equipment and Software [Member] | ||
Property and equipment, at cost | 409 | 365 |
Furniture and Fixtures [Member] | ||
Property and equipment, at cost | 157 | 157 |
Leasehold Improvements [Member] | ||
Property and equipment, at cost | 79 | 79 |
Production Equipment [Member] | ||
Property and equipment, at cost | 65 | 65 |
Office Equipment [Member] | ||
Property and equipment, at cost | $ 20 | $ 20 |
Note 7 - Accrued Liabilities -
Note 7 - Accrued Liabilities - Summary of Accrued Liabilities (Details) - USD ($) $ in Thousands | Sep. 30, 2021 | Dec. 31, 2020 |
Avenova contract liabilities | $ 579 | $ 730 |
Employee payroll and benefits | 396 | 632 |
Sublease security deposit | 0 | 198 |
Inventory purchases | 0 | 181 |
Consulting services | 0 | 98 |
Other | 350 | 276 |
Total accrued liabilities | $ 1,325 | $ 2,115 |
Note 8 - Commitments and Cont_3
Note 8 - Commitments and Contingencies (Details Textual) - USD ($) $ in Millions | Apr. 23, 2021 | Sep. 30, 2021 |
Proceeds from Legal Settlements | $ 0.3 | |
KBSIII Towers [Member] | ||
Lessee, Operating Lease, Renewal Term (Year) | 5 years | |
Prepaid Expenses and Other Current Assets [Member] | ||
Insurance Reimbursement | $ 0.3 |
Note 8 - Commitments and Cont_4
Note 8 - Commitments and Contingencies - Lease Expense (Details) - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2021 | Sep. 30, 2020 | Sep. 30, 2021 | Sep. 30, 2020 | |
Operating lease cost | $ 99 | $ 212 | $ 298 | $ 726 |
Sublease income | 0 | (105) | 0 | (421) |
Net lease cost | 99 | 107 | 298 | 305 |
Operational cash flow used for operating leases | $ 113 | $ 236 | $ 339 | $ 816 |
Weighted-average remaining lease term (in years) (Year) | 6 months | 1 year 6 months | 6 months | 1 year 6 months |
Weighted-average discount rate | 12.00% | 12.00% | 12.00% | 12.00% |
Note 8 - Commitments and Cont_5
Note 8 - Commitments and Contingencies - Schedule of Future Lease Payments (Details) - USD ($) $ in Thousands | Sep. 30, 2021 | Dec. 31, 2020 |
2021 | $ 114 | |
2022 | 88 | |
Total future minimum lease payments | 202 | |
Less imputed interest | (6) | |
Total | 196 | |
Operating lease liability | 195 | $ 416 |
Operating lease liability- non-current | 1 | $ 87 |
Total | $ 196 |
Note 9 - Related Party Note P_2
Note 9 - Related Party Note Payable (Details Textual) - USD ($) $ in Thousands | May 14, 2020 | Feb. 27, 2019 | Sep. 30, 2021 | Sep. 30, 2020 | Sep. 30, 2021 | Sep. 30, 2020 |
Pioneer Hong Kong [Member] | Promissory Note [Member] | ||||||
Debt Instrument, Face Amount | $ 1,000 | |||||
Debt Instrument, Periodic Payment, Interest | $ 300 | 200 | ||||
Repayments of Long-term Debt, Total | $ 1,000 | |||||
Debt Issuance Costs, Net, Total | $ 20 | |||||
Interest Expense, Total | $ 0 | $ 0 | $ 0 | $ 75 | ||
China Kington [Member] | ||||||
Brokering Fee, Percent | 2.00% | |||||
Consulting Agreement, Term (Year) | 1 year | |||||
Consulting Agreement, Amount | $ 100 |
Note 10 - Convertible Note (Det
Note 10 - Convertible Note (Details Textual) - Iliad Research and Trading, L.P. [Member] - Secured Convertible Promissory Note [member] - USD ($) $ in Thousands | Mar. 26, 2019 | Sep. 30, 2021 | Sep. 30, 2020 | Sep. 30, 2021 | Sep. 30, 2020 |
Debt Instrument, Face Amount | $ 2,200 | ||||
Debt Instrument, Interest Rate, Stated Percentage | 10.00% | ||||
Proceeds from Convertible Debt | $ 2,000 | ||||
Debt Instrument, Original Issue Discount | 200 | ||||
Debt Instrument, Fee Amount | 15 | ||||
Deferred Finance Costs Excluding Transaction Fees | $ 200 | ||||
Debt Instrument, Interest Rate During Period | 22.00% | 20.00% | |||
Interest Expense, Debt, Total | $ 0 | $ 16 | $ 0 | $ 215 |
Note 11 - Warrant Liability (De
Note 11 - Warrant Liability (Details Textual) - USD ($) $ in Thousands | Oct. 27, 2020 | Mar. 06, 2020 | Mar. 31, 2020 | Dec. 31, 2020 | Sep. 30, 2020 | Sep. 30, 2021 | Sep. 30, 2020 | Sep. 30, 2019 | Aug. 13, 2019 |
Class of Warrant or Right, Outstanding (in shares) | 7,067,000 | 7,082,000 | |||||||
Class of Warrant or Right, Exercised During Period (in shares) | 0 | ||||||||
Proceeds from Warrant Exercises | $ 6,800 | $ 0 | $ 7,094 | ||||||
Embedded Derivative, No Longer Bifurcated, Amount Reclassified to Stockholders' Equity | $ 0 | 9,293 | |||||||
The July 2011 Warrants [Member] | |||||||||
Class of Warrant or Right, Expired During Period (in shares) | 35,107 | 35,107 | |||||||
Class of Warrant or Right, Outstanding (in shares) | 0 | ||||||||
October 2015 Warrants [Member] | |||||||||
Class of Warrant or Right, Expired During Period (in shares) | 15,320 | 15,320 | |||||||
Class of Warrant or Right, Outstanding (in shares) | 0 | ||||||||
Class of Warrant or Right, Exercised During Period (in shares) | 22,680 | ||||||||
Proceeds from Warrant Exercises | $ 5 | ||||||||
Embedded Derivative, No Longer Bifurcated, Amount Reclassified to Stockholders' Equity | $ 12 | ||||||||
The 2019 Domestic Warrants [Member] | |||||||||
Class of Warrant or Right, Outstanding (in shares) | 0 | ||||||||
Warrants and Rights Outstanding | 4,900 | 4,900 | $ 3,100 | $ 3,100 | |||||
The 2019 Foreign Warrants [Member] | |||||||||
Warrants and Rights Outstanding | 4,200 | 4,200 | 2,000 | ||||||
The 2019 Ladenburg Warrants [Member] | |||||||||
Warrants and Rights Outstanding | $ 200 | $ 200 | $ 100 |
Note 11 - Warrant Liability - T
Note 11 - Warrant Liability - The Key Assumptions Used to Value the Warrants (Details) | Dec. 31, 2019 |
Measurement Input, Price Volatility [Member] | The 2019 Domestic Warrants [Member] | |
Warrants assumptions | 1.78 |
Measurement Input, Price Volatility [Member] | The 2019 Foreign Warrants [Member] | |
Warrants assumptions | 1.78 |
Measurement Input, Price Volatility [Member] | The 2019 Ladenburg Warrants [Member] | |
Warrants assumptions | 1.86 |
Measurement Input, Expected Term [Member] | The 2019 Domestic Warrants [Member] | |
Warrants assumptions | 4.57 |
Measurement Input, Expected Term [Member] | The 2019 Foreign Warrants [Member] | |
Warrants assumptions | 4.57 |
Measurement Input, Expected Term [Member] | The 2019 Ladenburg Warrants [Member] | |
Warrants assumptions | 4.05 |
Measurement Input, Risk Free Interest Rate [Member] | The 2019 Domestic Warrants [Member] | |
Warrants assumptions | 0.0025 |
Measurement Input, Risk Free Interest Rate [Member] | The 2019 Foreign Warrants [Member] | |
Warrants assumptions | 0.0027 |
Measurement Input, Risk Free Interest Rate [Member] | The 2019 Ladenburg Warrants [Member] | |
Warrants assumptions | 0.0022 |
Measurement Input, Expected Dividend Rate [Member] | The 2019 Domestic Warrants [Member] | |
Warrants assumptions | 0 |
Measurement Input, Expected Dividend Rate [Member] | The 2019 Foreign Warrants [Member] | |
Warrants assumptions | 0 |
Measurement Input, Expected Dividend Rate [Member] | The 2019 Ladenburg Warrants [Member] | |
Warrants assumptions | 0 |
Measurement Input, Share Price [Member] | The 2019 Domestic Warrants [Member] | |
Warrants assumptions | 1.18 |
Measurement Input, Share Price [Member] | The 2019 Foreign Warrants [Member] | |
Warrants assumptions | 1.54 |
Measurement Input, Share Price [Member] | The 2019 Ladenburg Warrants [Member] | |
Warrants assumptions | 1.17 |
Note 12 - Stockholders' Equit_2
Note 12 - Stockholders' Equity (Details Textual) - USD ($) $ / shares in Units, $ in Thousands | Oct. 27, 2020 | Mar. 06, 2020 | Mar. 31, 2020 | Jun. 30, 2021 | Dec. 31, 2020 | Sep. 30, 2020 | Jun. 30, 2020 | Mar. 31, 2020 | Sep. 30, 2019 | Jun. 30, 2019 | Dec. 31, 2015 | Mar. 31, 2015 | Sep. 30, 2011 | Sep. 30, 2021 | Sep. 30, 2020 | Jan. 15, 2021 | Aug. 13, 2019 | May 31, 2019 | Feb. 29, 2016 | Oct. 31, 2015 |
Preferred Stock, Shares Authorized (in shares) | 5,000,000 | 5,000,000 | ||||||||||||||||||
Preferred Stock, Shares Outstanding, Ending Balance (in shares) | 0 | 0 | ||||||||||||||||||
Proceeds from Issuance of Common Stock | $ 1,994 | $ 5,220 | ||||||||||||||||||
Payments of Stock Issuance Costs | $ 200 | |||||||||||||||||||
Class of Warrant or Right, Issued During Period (in shares) | 15,000 | |||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 1.63 | $ 1.63 | ||||||||||||||||||
Class of Warrant or Right, Outstanding (in shares) | 7,067,000 | 7,082,000 | ||||||||||||||||||
Class of Warrant or Right, Exercised During Period (in shares) | 0 | |||||||||||||||||||
Proceeds from Warrant Exercises | 6,800 | $ 0 | 7,094 | |||||||||||||||||
China Kington [Member] | ||||||||||||||||||||
Payments of Stock Issuance Costs | 200 | |||||||||||||||||||
Ladenburg Thalmann and Co. Inc. [Member] | ||||||||||||||||||||
Payments of Stock Issuance Costs | $ 300 | |||||||||||||||||||
Private Placement, Commission Percentage | 6.00% | |||||||||||||||||||
Payments of Stock Issuance Costs, Reimbursement of Expenses | $ 60 | |||||||||||||||||||
Payments of Stock Issuance Costs, Other | $ 300 | |||||||||||||||||||
The July 2011 Warrants [Member] | ||||||||||||||||||||
Class of Warrant or Right, Issued During Period (in shares) | 139,520 | |||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 139,520 | |||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 33.25 | $ 0.2061 | $ 1.81 | $ 5 | ||||||||||||||||
Class of Warrant or Right, Expired During Period (in shares) | 35,107 | 35,107 | ||||||||||||||||||
Class of Warrant or Right, Outstanding (in shares) | 0 | |||||||||||||||||||
March 2015 Short-term and Long-term Warrants [Member] | ||||||||||||||||||||
Class of Warrant or Right, Issued During Period (in shares) | 649,133 | |||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 649,133 | |||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | 0.2061 | 1.81 | $ 5 | |||||||||||||||||
Class of Warrant or Right, Expired During Period (in shares) | 7,419 | |||||||||||||||||||
Class of Warrant or Right, Outstanding (in shares) | 0 | |||||||||||||||||||
Class of Warrant or Right, Exercised During Period (in shares) | 70,000 | |||||||||||||||||||
Proceeds from Warrant Exercises | $ 14 | |||||||||||||||||||
March 2015 Warrants [Member] | Minimum [Member] | ||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 15 | |||||||||||||||||||
March 2015 Warrants [Member] | Maximum [Member] | ||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 16.25 | |||||||||||||||||||
March 2015 Warrants Expiring March 6, 2020 [Member] | ||||||||||||||||||||
Class of Warrant or Right, Issued During Period (in shares) | 278,200 | |||||||||||||||||||
March 2015 Warrants Expiring June 6, 2015 [Member] | ||||||||||||||||||||
Class of Warrant or Right, Issued During Period (in shares) | 370,933 | |||||||||||||||||||
October 2015 Warrants [Member] | ||||||||||||||||||||
Class of Warrant or Right, Issued During Period (in shares) | 442,802 | |||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 442,802 | |||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 5 | $ 0.2061 | $ 1.81 | |||||||||||||||||
Class of Warrant or Right, Expired During Period (in shares) | 15,320 | 15,320 | ||||||||||||||||||
Class of Warrant or Right, Outstanding (in shares) | 0 | |||||||||||||||||||
Class of Warrant or Right, Exercised During Period (in shares) | 22,680 | |||||||||||||||||||
Proceeds from Warrant Exercises | $ 5 | |||||||||||||||||||
The June 2019 Warrants [Member] | ||||||||||||||||||||
Class of Warrant or Right, Issued During Period (in shares) | 1,371,427 | |||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 1,371,427 | |||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 0.87 | |||||||||||||||||||
Class of Warrant or Right, Expired During Period (in shares) | 571,428 | |||||||||||||||||||
Class of Warrant or Right, Outstanding (in shares) | 0 | |||||||||||||||||||
Class of Warrant or Right, Exercised During Period (in shares) | 571,428 | 228,571 | ||||||||||||||||||
Proceeds from Warrant Exercises | $ 497 | $ 199 | ||||||||||||||||||
Class of Warrant or Right Call Feature Minimum Stock Price (in dollars per share) | $ 1 | |||||||||||||||||||
The June 2019 Warrants [Member] | China Kington [Member] | ||||||||||||||||||||
Payments for Commission, Exercise of Warrants | $ 29 | $ 12 | ||||||||||||||||||
Exercise of Warrants, Commission, Percent | 6.00% | 6.00% | 6.00% | |||||||||||||||||
The 2019 Domestic Warrants [Member] | ||||||||||||||||||||
Class of Warrant or Right, Issued During Period (in shares) | 4,198,566 | |||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 4,198,566 | |||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 1.15 | |||||||||||||||||||
Class of Warrant or Right, Outstanding (in shares) | 0 | |||||||||||||||||||
Warrants and Rights Outstanding | $ 4,900 | $ 3,100 | $ 4,900 | $ 3,100 | ||||||||||||||||
Payments of Stock Issuance Costs Allocated to Warrants | 200 | |||||||||||||||||||
Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs | $ 300 | |||||||||||||||||||
The 2019 Ladenburg Warrants [Member] | ||||||||||||||||||||
Class of Warrant or Right, Issued During Period (in shares) | 167,942 | |||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 167,942 | |||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 0.99 | $ 1.25 | $ 0.99 | |||||||||||||||||
Warrants and Rights Outstanding | $ 200 | $ 200 | 100 | |||||||||||||||||
Payments of Stock Issuance Costs Allocated to Warrants | $ 59 | |||||||||||||||||||
Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs | $ 65 | |||||||||||||||||||
The 2019 Foreign Warrants [Member] | ||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 0.99 | $ 0.99 | ||||||||||||||||||
Exercise of Warrants, Commission, Percent | 6.00% | 6.00% | ||||||||||||||||||
Warrants and Rights Outstanding | $ 4,200 | $ 4,200 | $ 2,000 | |||||||||||||||||
New Warrants [Member] | ||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 6,898,566 | 6,898,566 | ||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 1.65 | $ 1.65 | ||||||||||||||||||
Warrants and Rights Outstanding, Term (Year) | 5 years 6 months | 5 years 6 months | ||||||||||||||||||
TLF Bio Innovation 2021 Warrants [Member] | ||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 15,000 | |||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 0.6718 | |||||||||||||||||||
Warrants and Rights Outstanding, Term (Year) | 5 years | |||||||||||||||||||
ATM Program [Member] | ||||||||||||||||||||
Stock Issued During Period, Shares, New Issues (in shares) | 2,672,000 | 5,836,792 | ||||||||||||||||||
Proceeds from Issuance of Common Stock | $ 1,800 | $ 5,600 | ||||||||||||||||||
Payments of Stock Issuance Costs | $ 100 | $ 400 | ||||||||||||||||||
Private Placement [Member] | ||||||||||||||||||||
Payments of Stock Issuance Costs | $ 27 | |||||||||||||||||||
Private Placement [Member] | Three Accredited Investors [Member] | ||||||||||||||||||||
Stock Issued During Period, Shares, New Issues (in shares) | 1,371,427 | |||||||||||||||||||
Issuance of Stock and Warrants During the Period, Value | $ 2,400 | |||||||||||||||||||
Private Placement [Member] | Xiao Rui Liu [Member] | ||||||||||||||||||||
Issuance of Stock and Warrants During the Period, Value | 1,000 | |||||||||||||||||||
Private Placement [Member] | Hai Dong Pang [Member] | ||||||||||||||||||||
Issuance of Stock and Warrants During the Period, Value | 400 | |||||||||||||||||||
Private Placement [Member] | Ping Huang [Member] | ||||||||||||||||||||
Issuance of Stock and Warrants During the Period, Value | 1,000 | |||||||||||||||||||
Private Placement [Member] | China Kington [Member] | ||||||||||||||||||||
Payments of Stock Issuance Costs | $ 100 | |||||||||||||||||||
Private Placement, Commission Percentage | 6.00% | |||||||||||||||||||
August 2019 Common Stock Purchase Agreement [Member] | ||||||||||||||||||||
Stock Issued During Period, Shares, New Issues (in shares) | 4,198,566 | |||||||||||||||||||
Payments of Stock Issuance Costs | $ 500 | |||||||||||||||||||
Proceeds from Issuance of Stock and Warrants | $ 4,200 |
Note 12 - Stockholders' Equit_3
Note 12 - Stockholders' Equity - Outstanding Warrants (Details) shares in Thousands | 9 Months Ended |
Sep. 30, 2021$ / sharesshares | |
Outstanding warrants (in shares) | shares | 7,067 |
Outstanding warrants, weighted-average exercise price (in dollars per share) | $ / shares | $ 1.63 |
Warrants granted (in shares) | shares | 15 |
Warrants granted, weighted average exercise price (in dollars per share) | $ / shares | $ 0.67 |
Warrants exercised (in shares) | shares | 0 |
Warrants exercised, weighted average exercise price (in dollars per share) | $ / shares | $ 0 |
Warrants expired (in shares) | shares | 0 |
Warrants expired, weighted average exercise price (in dollars per share) | $ / shares | $ 0 |
Outstanding warrants (in shares) | shares | 7,082 |
Outstanding warrants, weighted-average exercise price (in dollars per share) | $ / shares | $ 1.63 |
Note 13 - Equity-based Compen_3
Note 13 - Equity-based Compensation (Details Textual) - USD ($) | Jan. 15, 2021 | Aug. 21, 2020 | Jul. 31, 2021 | Jul. 31, 2020 | Apr. 30, 2020 | Sep. 30, 2021 | Sep. 30, 2020 | Sep. 30, 2021 | Sep. 30, 2020 |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period (in shares) | 0 | 20,000 | 0 | 20,000 | |||||
Proceeds from Stock Options Exercised | $ 0 | $ 6,000 | $ 0 | $ 6,000 | |||||
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total | 1,200,000 | $ 1,200,000 | |||||||
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year) | 2 years 5 months 12 days | ||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares) | 291,000 | ||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares) | 1,228,000 | ||||||||
Share-based Payment Arrangement, Expense | 224,000 | 176,000 | $ 702,000 | $ 359,000 | |||||
Share-based Payment Arrangement, Nonemployee [Member] | |||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares) | 0 | ||||||||
Employees and Directors [Member] | |||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares) | 291,000 | 1,156,000 | |||||||
Nonemployees [Member] | |||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares) | 100,000 | ||||||||
Share-based Payment Arrangement, Expense | 73,000 | 17,000 | $ 180,000 | $ 27,000 | |||||
Share-based Payment Arrangement, Option [Member] | Ms. Gail Maderis [Member] | |||||||||
Share-based Payment Arrangement, Expense | $ 36,000 | ||||||||
Share-based Payment Arrangement, Option [Member] | Mr. Xiaopei Wang [Member] | |||||||||
Share-based Payment Arrangement, Expense | $ 17 | ||||||||
Restricted Stock [Member] | |||||||||
Share-based Payment Arrangement, Expense | 151,000 | $ 159,000 | $ 523,000 | $ 332,000 | |||||
Restricted Stock [Member] | Employees and Directors [Member] | |||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares) | 1,228,359 | 160,000 | |||||||
Restricted Stock [Member] | Mr. Mark Sieczkarek [Member] | |||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares) | 328,359 | 192,983 | |||||||
Share-based Payment Arrangement, Expense | $ 440,000 | ||||||||
The 2007 Omnibus Incentive Plan [Member] | Maximum [Member] | Incentive Stock Options (ISOs) [Member] | |||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year) | 10 years | ||||||||
The 2017 Omnibus Incentive Plan [Member] | |||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares) | 2,318,486 | 2,318,486 | |||||||
Share-based Compensation Arrangement by Share-based Payment Award, Annual Increase in Shares Authorized, Percentage of Outstanding Common Stock | 4.00% | 4.00% | |||||||
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized (in shares) | 1,671,303 | ||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant (in shares) | 2,325,118 | 2,325,118 | |||||||
The 2017 Omnibus Incentive Plan [Member] | Incentive Stock Options (ISOs) [Member] | |||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percentage of Stock Owned by Shareholder, Minimum | 10.00% | ||||||||
The 2017 Omnibus Incentive Plan [Member] | Share-based Payment Arrangement, Option [Member] | |||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year) | 4 years | ||||||||
The 2017 Omnibus Incentive Plan [Member] | Maximum [Member] | |||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year) | 10 years | ||||||||
The 2017 Omnibus Incentive Plan [Member] | Maximum [Member] | Incentive Stock Options (ISOs) [Member] | Shareholder of More Than 10% [Member] | |||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year) | 5 years | ||||||||
The 2017 Omnibus Incentive Plan [Member] | Minimum [Member] | |||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent | 100.00% | ||||||||
The 2017 Omnibus Incentive Plan [Member] | Minimum [Member] | Incentive Stock Options (ISOs) [Member] | Shareholder of More Than 10% [Member] | |||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent | 110.00% |
Note 13 - Equity-based Compen_4
Note 13 - Equity-based Compensation - Stock Options Outstanding (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands | 9 Months Ended | |
Sep. 30, 2021 | Dec. 31, 2020 | |
Outstanding awards (in shares) | 3,165 | |
Outstanding, weighted-average exercise price (in dollars per share) | $ 2.05 | |
Outstanding, weighted-average remaining contractual life (Year) | 7 years 7 months 6 days | |
Outstanding, aggregate intrinsic value | $ 633 | $ 189 |
Options granted (in shares) | 291 | |
Options granted, weighted-average exercise price (in dollars per share) | $ 0.74 | |
Restricted stock units granted (in shares) | 1,228 | |
Options forfeited/cancelled (in shares) | (249) | |
Options forfeited/cancelled, weighted-average exercise price (in dollars per share) | $ 2.39 | |
Outstanding awards (in shares) | 3,947 | |
Outstanding, weighted-average exercise price (in dollars per share) | $ 1.54 | |
Vested and expected to vest (in shares) | 3,601 | |
Vested and expected to vest, weighted-average exercise price (in dollars per share) | $ 1.64 | |
Vested and expected to vest, weighted-average remaining contractual life (Year) | 7 years 4 months 24 days | |
Vested and expected to vest, aggregate intrinsic value | $ 562 | |
Vested (in shares) | 1,802 | |
Vested, weighted-average exercise price (in dollars per share) | $ 2.77 | |
Vested, weighted-average remaining contractual life (Year) | 5 years 7 months 6 days | |
Vested, aggregate intrinsic value | $ 34 | |
Exercisable (in shares) | 1,802 | |
Exercisable, weighted-average exercise price (in dollars per share) | $ 2.77 | |
Exercisable, weighted-average remaining contractual life (Year) | 5 years 7 months 6 days | |
Exercisable, aggregate intrinsic value | $ 34 | |
Restricted Stock Units (RSUs) [Member] | ||
Restricted stock units vested (in shares) | (488) | |
Restricted stock units cancelled (in shares) | 0 |
Note 13 - Equity-based Compen_5
Note 13 - Equity-based Compensation - Weighted-average Assumptions Used in Determining the Value of Options Granted to Employees and Directors (Details) - Employees and Directors [Member] - $ / shares | 9 Months Ended | |
Sep. 30, 2021 | Sep. 30, 2020 | |
Expected price volatility | 163.95% | 160.57% |
Expected term (Year) | 6 years 2 months 8 days | 6 years 5 months 12 days |
Risk-free interest rate | 0.92% | 0.45% |
Dividend yield | 0.00% | 0.00% |
Weighted-average fair value of options granted during the period (in dollars per share) | $ 0.71 | $ 0.94 |
Note 13 - Equity-based Compen_6
Note 13 - Equity-based Compensation - Weighted-average Assumptions Used in Determining the Value of Options Granted to Non-employees (Details) - Nonemployees [Member] | 9 Months Ended |
Sep. 30, 2020$ / shares | |
Expected price volatility | 162.30% |
Expected term (in years) (Year) | 6 years 4 months 2 days |
Risk-free interest rate | 0.33% |
Dividend yield | 0.00% |
Weighted-average fair value of options granted during the period (in dollars per share) | $ 1.27 |
Note 13 - Equity-based Compen_7
Note 13 - Equity-based Compensation - Summary of Stock-based Compensation Expense Included in Results of Operations (Details) - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2021 | Sep. 30, 2020 | Sep. 30, 2021 | Sep. 30, 2020 | |
Stock-based compensation expense | $ 224 | $ 176 | $ 702 | $ 359 |
Research and Development Expense [Member] | ||||
Stock-based compensation expense | 2 | 8 | 8 | 22 |
Selling and Marketing Expense [Member] | ||||
Stock-based compensation expense | 53 | 29 | 118 | 49 |
General and Administrative Expense [Member] | ||||
Stock-based compensation expense | $ 169 | $ 139 | $ 576 | $ 288 |
Note 14 - License, Collaborat_3
Note 14 - License, Collaboration and Distribution Agreements (Details Textual) - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | ||||
Sep. 30, 2021 | Sep. 30, 2020 | Sep. 30, 2021 | Sep. 30, 2020 | Sep. 30, 2020 | Dec. 31, 2020 | |
Revenue from Contract with Customer, Including Assessed Tax | $ 1,840 | $ 2,170 | $ 5,780 | $ 8,046 | $ 8,046 | |
Avenova Product [Member] | ||||||
Revenue from Contract with Customer, Including Assessed Tax | 1,763 | 1,835 | 5,221 | 4,509 | ||
Avenova Direct [Member] | ||||||
Revenue from Contract with Customer, Including Assessed Tax | 1,200 | 1,000 | 3,800 | 2,400 | ||
McKesson Corporation [Member] | Avenova Product [Member] | ||||||
Contract with Customer, Liability, Revenue Recognized | 300 | $ 600 | 600 | $ 1,600 | ||
McKesson Corporation [Member] | Avenova Product [Member] | Accounts Payable and Accrued Liabilities [Member] | ||||||
Contract with Customer, Liability, Total | 600 | 600 | $ 700 | |||
McKesson Corporation [Member] | Avenova Product [Member] | Prepaid Expenses and Other Current Assets [Member] | ||||||
Contract with Customer, Rebate Liability, Current | $ 40 | $ 40 | $ 100 |
Note 14 - License, Collaborat_4
Note 14 - License, Collaboration and Distribution Agreements - Changes in Assets and Liabilities (Details) $ in Thousands | 9 Months Ended |
Sep. 30, 2021USD ($) | |
Contract Liabilities: Deferred Revenue, Balance at beginning of the period | $ 2 |
Contract Liabilities: Deferred Revenue, additions | 122 |
Contract Liabilities: Deferred Revenue, deductions | (2) |
Contract Liabilities: Deferred Revenue, Balance at the end of the period | 122 |
Contract Liabilities: Accrued Liabilities,Balance at beginning of the period | 573 |
Contract Liabilities: Accrued Liabilities, additions | 1,213 |
Contract Liabilities: Accrued Liabilities, deductions | (1,250) |
Contract Liabilities: Accrued Liabilities, Balance at the end of the period | 536 |
Contract Liabilities, Balance at beginning of the period | 575 |
Contract Liabilities, additions | 1,335 |
Contract Liabilities, deductions | (1,252) |
Contract Liabilities, Balance at the end of the period | $ 658 |
Note 14 - License, Collaborat_5
Note 14 - License, Collaboration and Distribution Agreements - Total Revenues (Details) - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | |||
Sep. 30, 2021 | Sep. 30, 2020 | Sep. 30, 2021 | Sep. 30, 2020 | Sep. 30, 2020 | |
Total sales, net | $ 1,840 | $ 2,170 | $ 5,780 | $ 8,046 | $ 8,046 |
Transferred over Time [Member] | |||||
Total sales, net | 573 | 434 | |||
Transferred at Point in Time [Member] | |||||
Total sales, net | $ 5,207 | $ 7,612 |
Note 15 - Employee Benefit Pl_2
Note 15 - Employee Benefit Plan (Details Textual) - USD ($) $ in Thousands | Jan. 01, 2022 | Sep. 30, 2021 | Sep. 30, 2020 | Sep. 30, 2021 | Sep. 30, 2020 |
The 401(k) Plan [Member] | |||||
Defined Contribution Plan, Employer Discretionary Contribution Amount | $ 0 | $ 0 | $ 0 | $ 0 | |
The 401K Plan Contribution Level One [Member] | Forecast [Member] | |||||
Defined Contribution Plan, Employer Matching Contribution, Percent of Match | 100.00% | ||||
The 401K Plan Contribution Level One [Member] | Forecast [Member] | Maximum [Member] | |||||
Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay | 3.00% | ||||
The 401K Plan Contribution Level Two [Member] | Forecast [Member] | |||||
Defined Contribution Plan, Employer Matching Contribution, Percent of Match | 50.00% | ||||
The 401K Plan Contribution Level Two [Member] | Forecast [Member] | Maximum [Member] | |||||
Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay | 5.00% | ||||
The 401K Plan Contribution Level Two [Member] | Forecast [Member] | Minimum [Member] | |||||
Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay | 3.00% |
Note 16 - Related Party Trans_3
Note 16 - Related Party Transactions (Details Textual) - USD ($) $ in Thousands | Nov. 17, 2020 | Sep. 30, 2021 | Sep. 30, 2020 | Sep. 30, 2021 | Sep. 30, 2020 | Dec. 31, 2020 |
Accounts Receivable, Related Parties | $ 100 | $ 100 | $ 200 | |||
Accounts Payable, Related Parties | 0 | $ 0 | $ 8 | |||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares) | 291,000 | |||||
Share-based Payment Arrangement, Expense | 224 | $ 176 | $ 702 | $ 359 | ||
Share-based Payment Arrangement, Nonemployee [Member] | ||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares) | 0 | |||||
Share-based Payment Arrangement, Nonemployee [Member] | Eric Wu [Member] | ||||||
Share-based Payment Arrangement, Expense | $ 31 | $ 0 | $ 91 | $ 0 | ||
Partner and Senior Vice President of China Kington [Member] | Share-based Payment Arrangement, Nonemployee [Member] | ||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares) | 300,000 | |||||
Partner and Senior Vice President of China Kington [Member] | Share-based Payment Arrangement, Nonemployee [Member] | Share-based Payment Arrangement, Option [Member] | ||||||
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year) | 1 year |
Note 16 - Related Party Trans_4
Note 16 - Related Party Transactions - Related Party Revenue, Cost of Goods Sold, and Expenses (Details) - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2021 | Sep. 30, 2020 | Sep. 30, 2021 | Sep. 30, 2020 | |
Total related party revenue | $ 0 | $ 0 | $ 175 | $ 173 |
Cost of goods sold | 0 | 0 | 131 | 90 |
Total related party expenses | 0 | 160 | 0 | 251 |
Director Bob Wu [Member] | ||||
Total related party expenses | 0 | 0 | 0 | 50 |
China Kington [Member] | ||||
Total related party expenses | 0 | 160 | 0 | 201 |
China Kington [Member] | The 2019 Foreign Warrants [Member] | ||||
Total related party expenses | 0 | 160 | 0 | 160 |
China Kington [Member] | Broker Fee for the Exercise of the June 2019 Warrants [Member] | ||||
Total related party expenses | 0 | 0 | 0 | 41 |
NeutroPhase [Member] | ||||
Total related party revenue | 0 | 0 | 175 | 173 |
Cost of goods sold | $ 0 | $ 0 | $ 131 | $ 90 |
Note 17 - Paycheck Protection_2
Note 17 - Paycheck Protection Program (Details Textual) - USD ($) $ in Thousands | May 24, 2021 | May 06, 2020 | Sep. 30, 2021 | Sep. 30, 2020 | Sep. 30, 2021 | Sep. 30, 2020 |
Paycheck Protection Program CARES Act [Member] | ||||||
Other Nonoperating Income | $ 0 | $ 432 | $ 0 | $ 901 | ||
Paycheck Protection Program CARES Act [Member] | Wells Fargo Bank [Member] | ||||||
Proceeds from Issuance of Long-term Debt, Total | $ 900 | |||||
Gain (Loss) on Extinguishment of Debt, Total | $ 900 |
Note 18 - Dermadoctor Llc Acq_2
Note 18 - Dermadoctor Llc Acquisition (Details Textual) | Dec. 31, 2021 |
DERMAdoctor [Member] | Forecast [Member] | |
Business Acquisition, Percentage of Voting Interests Acquired | 100.00% |
Note 19 - Subsequent Events (De
Note 19 - Subsequent Events (Details Textual) | Nov. 02, 2021USD ($)$ / sharesshares |
Subsequent Event [Member] | |
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 37,500,000 |
Series B Preferred Stock [Member] | |
Stock Issued During Period, Shares, New Issues (in shares) | 15,000 |
Series B Preferred Stock [Member] | Subsequent Event [Member] | |
Preferred Stock, Par or Stated Value Per Share (in dollars per share) | $ / shares | $ 0.01 |
Preferred Stock, Convertible, Shares Issuable (in shares) | 37,500,000 |
Proceeds from Issuance of Preferred Stock and Preference Stock | $ | $ 15,000,000 |